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 Abstract 
Several alternatively-spliced mRNA transcripts of the follicle stimulating hormone 
receptor (FSHR) have been identified in sheep, including FSHR-1 (G protein-coupled form), 
FSHR-2 (dominant negative form), and FSHR-3 (growth factor type-1 form).  Coupling of the 
FSHR to signaling pathways which activate different downstream effectors leads to speculation 
that specific splice variants may be transcribed under differing physiological conditions.   
This is the first study to correlate expression patterns of FSHR-1, FSHR-2, and FSHR-3 
and development of follicles in the mature sheep ovary.  In Experiment 1, 8 Suffolk-cross ewes 
were allowed to come into estrus naturally and were euthanized 24 (n=3), 36 (n=3), and 48 (n=2) 
hours after the onset of estrus.  In Experiment 2, 7 Suffolk-cross ewes received CIDRs for 14 
days.  At CIDR removal, PMSG (500IU) was administered to treatment ewes (n=3), while 
controls (n=4) received no PMSG.  Ewes were euthanized 24 (n=4; 2 CIDR only, 2 PMSG) or 36 
(n=3; 2 CIDR only, 1 PMSG) hours later.  All visible follicles were aspirated and pooled 
according to follicular diameter:  small (≤ 2.0 mm), medium (2.1-4.0 mm), large (4.1-6.0 mm), 
and preovulatory (≥ 6.1 mm).  Granulosa cells were separated from follicular fluid by 
centrifugation.  Total RNA was extracted from granulosa cells (GC) and reversed transcribed.  
The resulting cDNA was subjected to qPCR, using primer sets designed to amplify each variant 
specifically.   
For Experiment 1, regardless of time after onset of estrus, relative expression of FSHR-3 
exceeded that of both FSHR-1 and FSHR-2 in medium follicles (p < 0.01), and tended to be 
higher in small follicles (p=0.09).  For Experiment 2, treatment with PMSG did not significantly 
alter expression patterns of FSHR variants (p=0.18).  The FSHR-3 was expressed higher than 
FSHR-2 in all follicle sizes (p < 0.01) and was numerically more highly expressed than FSHR-1, 
although this difference was not significant (p > 0.11). 
These experiments show that in addition to the well characterized G protein-coupled form 
of the FSHR, alternatively spliced variants of the FSHR may participate in follicular dynamics 
during the first follicular wave of the sheep estrous cycle.  Furthermore, these results would 
indicate that an “alternatively” spliced form of the FSHR (FSHR-3) is the predominant form of 
the FSHR in the sheep. 
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CHAPTER 1 - LITERATURE REVIEW 
Introduction 
Follicular development begins before birth in some species, including the sheep.  The 
sheep fetus begins follicular growth approximately 100 days into gestation, or 50 days before 
birth [1].  By day 135 of gestation, the first antral follicle appears [2].  At birth, germ cell 
division is complete, and each follicle contains an arrested primary oocyte that progresses no 
further than the diplotene stage of meiosis I.  Oocyte growth remains arrested until a follicle 
undergoes recruitment, selection, and is exposed to the preovulatory LH surge. 
The process of follicular development is dependent upon endocrine support which is 
provided by gonadotropin hormones, including follicle stimulating hormone (FSH) and 
luteinizing hormone (LH).  Follicle stimulating hormone has been shown to have many functions 
during follicular growth [3].  It is intriguing that one hormone could promote different responses 
from follicles growing under similar conditions.  One possibility for different modes of action 
from the same hormone may be due to the receptor to which it binds [4]. 
The follicle stimulating hormone receptor (FSHR) is a large glycoprotein hormone 
receptor, located within ovarian follicles on granulosa cells.  In 1993, the ovine G protein 
coupled form of the FSHR (FSHR-1) was cloned and sequenced [5], based on DNA sequences 
previously described for the rat [6].  At that time, several alternatively spliced variants of the 
ovine FSHR were found [5, 7].  In-vitro studies determined that two variants, FSHR-2 and 
FSHR-3, would likely have functional significance [8, 9].  FSHR-2 is thought to act as a 
dominant-negative receptor and prevent downstream signaling [8].  FSHR-3 is thought to act as a 
growth factor type I receptor and stimulate proliferative pathways [9].  These alternative 
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signaling pathways may help to explain the diverse actions of FSH during follicular 
development. 
Since the first in-vitro studies, little research has been conducted to examine the in vivo 
expression of FSHR variants.  In order to gain a clearer picture of the actions of both FSH and 
FSHR variants during follicular development, it is necessary to look at the pattern of expression 
of FSHR variants at different times during the estrous cycle.  If variants are differentially 
expressed, further studies may be needed to determine the functions of the newly discovered 
variants. 
Follicular Development 
 At any given time after the first follicles are formed, follicles of most developmental 
stages can be found within the ovary.  The least developed follicle type is the primordial follicle. 
Resting primordial follicles have a single layer of flattened granulosa cells surrounding an ovoid 
or spherical oocyte [10].  The majority of a follicle’s life is spent in the resting primordial pool.  
It is not completely clear what mechanisms cause some resting primordial follicles to become 
activated, and join the group of growing follicles.  When cortical pieces of ovary with large 
numbers of primordial follicles are grown in culture, the vast majority of primordial follicles 
spontaneously activate and start growing [11].  This is in sharp contrast to the natural slow 
progression of follicles out of the resting pool.  This suggests that in vivo, inhibitory factors 
(from cells distinct from those found within follicles) keep the number of activating primordial 
follicles in check [12]. 
Once resting primordial follicles are activated, they begin to express markers of cell 
proliferation, such as proliferating cell nuclear antigen (PCNA) [11].  The layer of flattened 
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granulosa cells begin to change shape and become cuboidal as they transition to primary follicles 
[10].  Some primary follicles express FSH receptors [13]; however, it is unclear to what extent 
they are able to respond to FSH.  Two growth factors have been demonstrated to be essential for 
primary to secondary follicle transition in sheep [14]:  Growth and Differentiation Factor 9 
(GDF9) and Bone Morphogenetic Protein 15 (BMP15) [15-17].  Sheep that are immunized 
against either GDF9 or BMP15 fail to have follicular growth beyond the primary stage [15, 18].  
There are also five naturally occurring point mutations in BMP15 in breeds such as the 
Cambridge and Belclare [17].  Each mutation causes the same phenotype.  Ewes heterozygous 
for the BMP15 mutation have increased fertility; yet ewes homozygous for the BMP15 mutation 
have arrested follicular development at the primary stage [14, 17, 19].  This affirms that BMP15 
exerts negative inhibition on follicular development.  Removal of a single copy of the gene 
allows more follicles to remain viable.  However, when both copies of the gene are affected, 
follicular development ceases, as BMP15 is needed for primary to secondary follicle transition 
[15, 17]. 
A natural point mutation in GDF9 also exists [16].  As with the BMP15 mutation, ewes 
homozygous for the GDF9 mutation are infertile, but heterozygotes have increased fertility.  At 
least one functioning copy of GDF9 and BMP15 are needed for primary to secondary follicle 
transition. 
Secondary follicles have two layers of cuboidal granulosa cells and also have a theca 
interna layer on the outer boundary of the basement membrane [2].  Because many enzymes 
needed for steroidogenesis are not yet expressed by theca cells, it is thought that they are not 
steroidogenically active until the large preantral stage [20].  In sheep, all secondary follicles were 
shown to express FSHR mRNA in granulosa cells [13].  Even though the receptor is present, it is 
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accepted that follicle development to the antral (< 0.23 mm) stage is not completely dependent 
upon gonadotropins, but is gonadotropin responsive [21]. 
Tertiary follicles have more than two layers of cuboidal granulosa cells, and the 
formation of a small antrum, or fluid-filled cavity.  Before antrum formation, follicle growth is 
slow, taking about 130 days between activation to antrum formation.  After antrum formation, 
follicles grow more quickly, as it only takes about 45 days from antrum formation to reach 
preovulatory size [22].  Formation of the antrum pushes the oocyte to one side of the follicle.  
Some granulosa cells remain in contact with the oocyte (cumulus GC), while others form layers 
on the inside of the basement membrane (mural GC).  Once sheep follicles reach 2 mm in 
diameter, they are considered to be gonadotropin dependent.  After reaching that diameter, if 
follicles do not receive adequate gonadotropin support, they will undergo atresia.  This was 
illustrated in sheep by Dufour et al. (1979), when only 4 days post hypophysectomy all “large” 
antral follicles began to undergo atresia [23].  If antral follicles receive adequate gonadotropin 
support, they will continue to grow. 
One important function of antral follicles is to begin producing the steroid hormones, 
estrogen and progesterone.  Theca interna cells have enzymes which convert pregnenolone to 
androstenedione.  Granulosa cells have enzymes which convert androgens to estrogens [24]. Free 
cholesterol is shuttled to the mitochondria of the cell, where it undergoes side chain cleavage by 
the enzyme C27 side-chain cleavage P450.  This renders the compound pregnenolone which is 
transported to the smooth endoplasmic reticulum.  Pregnenolone can then enter one of two 
pathways:  the 5-ene-3β-hydroxy (5-ene) pathway or the 4-en-3-oxo (4-en) pathway.  
Pregnenolone must enter the 4-en pathway to be converted to progesterone.  There are many 
intermediate compounds that can be formed depending on the enzyme repertoire of the cell, and 
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the order in which enzymes are encountered.  Estradiol can be formed after several intermediates 
are converted to testosterone or estrone.  Testosterone is converted to estradiol by aromatase 
P450.  After synthesis, steroids can enter the bloodstream and act in an endocrine manner.  
Steroids contribute to follicular growth through both positive and negative feedback 
mechanisms. 
In sheep, often more than one follicle per estrous cycle escapes atresia, grows to the 
preovulatory (or Graafian) follicle size and ultimately ovulates.  Follicular growth from 2 mm to 
preovulatory size (≥ 6 mm) is very rapid, occurs within a day or two after the corpus luteum 
begins to regress.  In order for a follicle to escape atresia, it must acquire LH receptors in the GC 
layer.  It is unclear what mechanisms allow transcription of LH receptor in the granulosa cell 
layer in the future “dominant” follicles, while other “subordinate” follicles do not acquire LH 
receptor. 
Waves of Follicular Growth 
In sheep, there has been considerable controversy about whether or not follicular 
development occurs in waves.  Follicular waves were originally defined in cattle by Rajakoski 
(1960), as the changes in the number of follicles among the days of the estrous cycle [25].  
Rajakoski developed this definition based upon the patterns of follicular growth he observed 
from ovaries of cattle he obtained at slaughter.  He noted that more follicles were present on 
certain days of the estrous cycle, and postulated that two “waves” of follicular development 
occur in the cow.  The use of ultrasonography allowed Rajakoski’s hypothesis to be proven in 
cattle by Pierson and Ginther (1988) [26].  In cattle, it is now widely accepted that follicular 
growth occurs in waves [27]. 
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Follicular waves in sheep were noted as early as 1971 [28], with various studies agreeing 
[29] or disagreeing [30] with the notion of waves in sheep.  Evans et al. (2002) published 
evidence in favor of follicular development in waves during the estrous cycle of sheep [31].  
These investigators wanted to statistically characterize the number and size of follicles present 
on each day of the cycle, as lack of statistical proof had been one of the main arguments against 
follicular waves in sheep [32].  Monovulatory species of sheep were monitored via 
ultrasonography throughout one or two estrous cycles and two to four waves of follicular 
development were seen.  Considering that the sheep estrous cycle is relatively short, ewes with 
more than two follicular waves undergo rapid follicular turnover.  It is suspected that earlier 
studies which were unable to detect waves of follicular growth [30] may be because the turnover 
rate was too great [31]. 
Although waves of follicular growth are generally characterized by monitoring antral 
follicle development via ultrasonography, the process begins with activation of primordial 
follicles.  In sheep, it is estimated that 2-3 follicles are activated from the primordial pool each 
day [33].  It takes about 180 days for one of those follicles to reach an ovulatory diameter [22].  
Once these follicles reach 2 mm in diameter, they are considered gonadotropin responsive.  It is 
from this pool of follicles that a growing cohort emerges [31].  Factors that contribute to 
emergence are largely unknown, but it occurs during a transient rise in circulating FSH 
concentrations [34, 35].  Once this cohort is recruited, there is a common growth phase in which 
no follicles exert dominance over the others, followed by the process of selection.  Several 
intrafollicular factors are thought to play a role in selection, including IGF-1 and its binding 
proteins [36].  After selection, one or two follicles will gain LHR in the granulosa cell layer.  As 
circulating FSH declines, these follicles are then able to respond to LH to meet their 
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gonadotropin requirement.  Selection is accompanied by diameter deviation, in which the 
follicles that have become LH dependent grow at a faster rate than follicles which still require 
FSH for growth [31]. 
Although follicular waves occur during the luteal and follicular phases of the estrous 
cycle, the dominant follicles will only ovulate if no functioning corpora lutea are present.  If 
functional CL are present, the dominant follicles will regress.  If no CL is present, dominant 
follicles will continue to grow and secrete more estradiol.  As higher concentrations of estradiol 
enter circulation, they exert a negative feedback effect on the hypothalamus and anterior 
pituitary, effectively starving out follicles which did not acquire LHR in the GC layer.  Estradiol 
is known to have a biphasic effect, meaning at low concentrations, its effects are different than at 
high concentrations [37].  As concentrations increase, finally a threshold is reached which causes 
the LH surge and ultimately ovulation. 
In sheep, true dominance of one follicle over another probably does not occur, as often 
times more than one follicle will ovulate.  However, there are differences between follicles that 
ovulate (dominant) and those that do not (subordinate), in steroidogenic capacity, diameter, and 
ability to express LHR in the granulosa cell layer [38].  Evans et al. (2002), showed that in 
monovulatory sheep, when the largest follicle is ablated, the next largest follicle will continue to 
grow, rather than succumb to atresia [35].  Thus, in monovulatory sheep breeds follicular 
dominance does occur. 
Gonadotropins 
Gonadotroph cells are located in the anterior pituitary, and are responsible for the 
synthesis and release of the pituitary gonadotropins, LH and FSH.  Gonadotropins are large 
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glycoprotein hormones that share sequence homology among α subunits, but differ in β subunit 
composition. It is the β subunit that determines the biological activity of the hormone. 
The mature α subunit, common among several members of the glycoprotein hormone 
family, consists of 92 amino acids [39].  The α subunit is encoded by a single gene that has four 
exons.  The α protein has 10 cysteine residues that are involved in intrasubunit disulfide bonds.  
Two Asparagine residues (located within glycosylation consensus sequences) serve as sites for 
N-Linked glycosylation, which contribute to hormone half-life [40].  Transcription of the α 
subunit is controlled by the pulse frequency of GnRH, with faster pulses causing a higher rate of 
α subunit transcription [41]. 
Pulse frequency of GnRH also controls the rate of transcription of gonadotropin beta 
subunits.  It is thought that low pulse frequency of GnRH favors transcription of the FSH-β 
subunit, while increased pulse frequency favors LH-β transcription, as reviewed by [41].  
Transcriptional control of FSH is also controlled by activin, follistatin, and inhibin.  Activin and 
follistatin act through the type II activin receptor (ActRII); inhibin acts through the transforming 
growth factor-β (TGF-β) receptor to sequester ActRII and prevent its binding to activin or 
follistatin.  Inhibin is produced by growing follicles on the ovary, and acts in an endocrine 
manner by exerting negative feedback on gonadotroph cells of the anterior pituitary and 
decreasing FSH production [35].  Activin increases FSH production by binding to the activin 
receptor-like kinase 4 (ALK-4; type I receptor) on gonadotroph cells to stimulate the 
transcription factors Smad3 and 4.  Activin is negatively regulated by Smad7, which is 
upregulated by Smad3 and/or 4; activin is also capable of decreasing its own production (and 
subsequently that of FSH) by binding to ActRII on folliculostellate cells, which increases 
production of follistatin.  Follistatin decreases FSH production both by binding to activin and the 
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ActRII, each of which would prevent phosphorylation of ALK-4, and eventual transcription of 
FSH-β (as reviewed by [42]). 
Gonadotropin Receptors 
The gonadotropin receptors are glycoprotein hormone receptors that belong to the G 
protein-coupled receptor (GPCR) superfamily, specifically, the family of rhodopsin-like 
receptors.  The luteinizing hormone receptor (LHR), follicle stimulating hormone receptor 
(FSHR), thyrotropin stimulating hormone receptor (TSHR) and chorionic gonadotropin receptors 
are all members of the GPCR superfamily.  These receptors all contain seven transmembrane 
segments, and each is thought to interact with guanine nucleotide binding proteins (G proteins) 
to transduce signaling. 
Follicle Stimulating Hormone Receptor Gene 
The FSHR is approximately 85,000-100,000 base pairs in length and consists of 9 introns 
and 10 exons [43].  The promoter region of the FSHR has been described; however, the specific 
elements that regulate gene transcription remain an enigma.  The strongest promoter activity is 
located -200 to +163 relative to the transcription start site; the transcription start site is located    
-163 base pairs relative to the translation start site.  No TATA or CCAAT boxes (which are often 
absent in genes that are constitutively expressed) are found near the transcription start site; 
however, many potential regulatory elements have been identified.  One putative regulatory 
sequence of interest was a palindrome sequence <GGGTCAC GTGACCC> that was very 
similar, but not identical, to an estrogen response element.  An E-box element was identified, to 
which upstream stimulatory factor (USF) 1 and 2 were shown to bind [44].  A GT/CACC box 
10 
 
was also identified; zinc finger proteins could potentially bind to this site.  Two possible CRE-
like elements were found at -1473 to -1466 and -673 to -666, relative to the translation start site.  
CRE elements serve as a binding site to the trans-acting transcription factor CREB, which is 
activated by increased intracellular levels of cAMP.  An AP-1 binding site was identified -1483 
to -1491, and an AP-1 reverse binding site was found at -1807 to -1799 bp.  Several testes-
specific motifs were found, including a Y box type, PuF, AABS, and C mos like elements.  
These motifs are thought to be important in maintaining testes-specific expression.  No elements 
were identified that might be ovary-specific.  Factors that are known to increase expression of 
FSHR include FSH, cAMP, activin, and transforming growth factor-β (TGF-β), while 
transforming growth factor-α decreases FSHR expression [45]. 
Follicle Stimulating Hormone Receptor Structure 
The FSHR was first cloned and sequenced in 1990 [6] by screening a rat Sertoli cell 
cDNA library.  Using the same procedures, Yarney et al. (1993), cloned ovine FSHR mRNA 
from a sheep Sertoli cell library [5].  The ovine FSHR is 2431 nucleotides in length, and codes 
for a protein consisting of 695 amino acids (the first 18 residues code for the signal peptide; the 
mature protein is 675 amino acids in length; [6]).  The FSHR is composed of three domains:  an 
extracellular ligand binding domain, a domain with seven membrane spanning segments, and an 
intracellular domain.  The extracellular ligand binding domain is large and has 348 amino acid 
residues with three N-linked glycosylation sites [6].  Glycosylation is thought to convey 
protection from degradation in the extracellular environment, and may be involved with hormone 
binding and activation of the receptor.  The membrane spanning domain consists of 264 residues, 
and serves to anchor the receptor into the cell membrane.  Amino acids which span the 
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membrane (about 23 amino acids per membrane spanning segment) are arranged in an alpha 
helical manner.  Amino acids that connect the membrane spanning segments form loops that 
protrude either intra- or extra-cellularly; intracellular loops are important for interaction with G 
proteins, while extracellular loops may be involved in hormone binding and/or activation of the 
receptor [46].  The FSHR is thought to preferentially associate with Gs proteins[46].  The 
intracellular domain has 63 amino acids, and also aids in interaction with G proteins that 
transduce receptor signaling to downstream effectors. 
G Proteins 
G proteins are intracellular proteins, which associate with the intracellular loops and 
carboxyl tail of some receptors (as reviewed by [47]).  Many G proteins may interact with a 
single receptor.  There are both stimulatory (Gs) and inhibitory (Gi) G proteins, and monomeric 
and heterotrimeric G proteins.  Monomeric G proteins have a single, small α unit.  Monomeric G 
proteins usually interact with growth factor-type receptors.  The FSHR associates with 
heterotrimeric G proteins which have α, β, and γ subunits.  The β and γ subunits are permanently 
bound together, however the α subunit can detach from the complex.  The α, β, and γ subunits 
are bound in the G protein complex until activated by receptor/ligand binding.  In its inactive 
form, the α subunit is bound by guanine diphosphate (GDP).  Once activated, GDP is replaced 
with guanine triphosphate (GTP), by guanine nucleotide exchange factor (GEF).  The alpha 
subunit, with bound GTP, then detaches from the β and γ subunits and activates the effector 
enzyme adenylyl cyclase, which converts adenosine triphosphate (ATP) to cyclic adenosine 
monophosphate (cAMP).  Increased intracellular levels of cAMP act as a second messenger, and 
cause activation of Protein Kinase A (PKA).  PKA is composed of four subunits, two catalytic 
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and two regulatory.  The regulatory units keep the catalytic units inactive in the absence of 
cAMP.  When increased cAMP is present, cAMP binds the regulatory subunits of PKA and they 
detach from the catalytic subunits.  The catalytic subunits are then active and can phosphorylate 
many intracellular target proteins.  One of the main targets of PKA is the cAMP response 
element binding protein (CREB), a transcription factor.  Upon activation by PKA, CREB 
increases gene transcription [47]. 
Cessation of signaling 
Adenylyl cyclase will continue to convert ATP to cAMP until GTP is hydrolyzed to 
GDP.  Once hydrolyzed, the α subunit will reassociate with the β and γ subunits.  Excess cAMP 
is degraded by phosphodiesterase, and downstream signaling ceases [47]. 
Gene Splicing 
Genes have both exons or coding sequences, and introns, or non-coding sequences.  
When DNA is transcribed into RNA, both introns and exons are copied, which yields pre-
mRNA.  Transcription occurs within the nucleus of the cell, and is initiated when appropriate 
transcription factors interact with the promoter of the gene.  RNA polymerase II is responsible 
for transcribing DNA into pre-mRNA.  Pre-mRNA undergoes splicing to remove introns prior to 
its translation.  Splicing occurs within the nucleus in a spliceosome.  Spliceosomes consist of 
five small nuclear ribonucleoproteins (snRNP) [48].  Each snRNP has 1-2 snRNAs and several 
proteins. Small nuclear ribonucleoproteins recognize cis-acting elements, which allow them to 
pinpoint exon/intron boundaries, and attach to the elements in a step-wise manner [48].  After 
assembly, the spliceosome removes introns through two trans-esterification reactions.  Introns 
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are looped out and degraded.  Alternative splicing of RNA can also occur, which involves 
removing exons that contain coding sequences.  Removal of specific exons can still result in 
mRNA that is translated into functional proteins.  It is estimated that about 50% of human genes 
undergo alternative splicing [49].   After splicing, the resulting mRNA is then further processed 
by addition of a poly-A tail.  This tail conveys stability to the mRNA, and delays its degradation 
as it travels from the nucleus to the rough endoplasmic reticulum to be translated. 
FSHR Alternative Splice Variants 
When the sheep FSHR was identified by screening a sheep Sertoli cell cDNA library [5], 
Northern blot analysis of FSHR mRNA revealed transcripts of different sizes, providing the first 
evidence that sheep FSHR mRNA was able to undergo alternative splicing and produce 
transcript variants.  Once it was apparent that alternative splicing occurred, updated 
nomenclature was necessary to distinguish each variant from another; the G protein-coupled 
form of the receptor became known as FSHR-1. 
The first alternatively spliced transcript to be identified and described was HK201 (later 
renamed FSHR-2 [5]).  The FSHR-2 consists of 652 amino acids [5, 50].  The FSHR-2 has high 
sequence homology with FSHR-1.  The sequence for FSHR-2 is the same as FSHR-1 until it 
diverges at amino acid residue 625, at which point, the sequence differs for the last 27 residues.  
Exons 1-9 are the same for FSHR-1 and FSHR-2 however, FSHR-2 has a truncated exon 10 
spliced to a putative exon 11 [50].  The truncation in exon 10 is thought to affect receptor 
signaling.  Although FSHR-2 has been shown to bind FSH with high affinity, downstream 
signaling did not occur [8].  In fact, when FSHR-2 and FSHR-1 were cotransfected into HEK 
293 cells and treated with FSH, only a small increase in intracellular cAMP was detectable, in 
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contrast to the large increase normally caused by FSHR-1.  These researchers speculated that 
FSHR-2 attenuated the actions of FSHR-1, leading the authors to conclude that FSHR-2 acts as a 
dominant negative form of the FSHR [8]. 
Another alternatively spliced transcript called HK18 (later renamed FSHR-3) was 
described around the same time [7].  FSHR-3 is composed 259 amino acid residues.  The first 
223 amino acid residues are identical to the G protein-coupled form of the receptor, with the 
final 36 residues differing from FSHR-1 [7].  It is of note that these 36 residues do correspond to 
the carboxy terminus of FSHR-2 [50].  The FSHR-3 shares exons 1-8 in common with FSHR-1, 
and is spliced at nucleotide 392; exons 9 and 10 are removed and a putative exon 11 is added.  
Because the extracellular domain of the well-characterized G protein-coupled form is encoded by 
exons 1-9, and the majority of the domain is present in exons 1-8, FSHR-3 has many of the 
leucine rich repeats that are needed for hormone binding; thus, FSHR-3 is capable of binding 
FSH with high affinity [9]. 
Although FSHR-3 is lacking exon 10, which codes for the seven transmembrane domains 
that are the hallmark of G protein-coupled receptors, in several different transfection studies 
FSHR-3 was shown to be expressed at the cell surface [9, 51, 52].  Apparently, the single 
transmembrane domain encoded by exon 11 is sufficient for insertion into the plasma membrane.  
It was because of the single transmembrane domain, and the signal transduction pathways 
activated by FSHR-3, that it was placed into the growth factor type 1 receptor class. 
In contrast to FSHR-1, FSHR-3 is thought to act in a cAMP-independent fashion.  When 
stimulated by FSH, it has been shown to activate a mitogen-activated protein kinase (MAPK) 
pathway, specifically the extracellular-regulated kinase (ERK) signaling cascade [52].  The ERK 
cascade is involved in cell proliferation and is regulated by Ras. The ERK cascade consists of 
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three kinase modules:  a mitogen-activated protein kinase (MAPK), which is activated by a 
MAPK/ERK kinase (MEK), which is subsequently activated by another MEK kinase (MEKK).  
The ERK cascade consists of Raf isoforms ERK1/ERK2 and MEK1/2.  Experiments done by 
Babu et al. (2000), illustrated the activation of the ERK cascade by FSHR-3 is Ca2+ dependent 
[52].  Touyz et al. (2000), showed that activation of FSHR-3 cause a dramatic increase in Ca2+ in 
transfected HEK 293 cells [51].  This calcium increase was thought to be mediated by L-type 
voltage dependent calcium channels.  The significance of these findings relates to the increases 
in cell proliferation that were observed shortly after calcium influx and activation of the ERK 
signaling cascade.  These studies illustrate that FSH is likely to stimulate cell proliferation 
directly through FSHR-3. 
Seasonality 
Sheep are short-day breeders, and have a breeding season which extends from September 
through February.  Ambient day length is important to maintain the circannual rhythm of the 
breeding season.  Maintaining a specific seasonal breeding period from year to year ensures that 
offspring will be born during a time in which conditions are optimal for survival. 
Day length has a direct impact on the secretion of the hormone melatonin [53].  
Melatonin is produced by the pinealocytes of the pineal gland, and is only synthesized and 
secreted during periods of darkness.  Melatonin actively determines the reproductive response to 
photoperiod by stimulating the hypothalamus to increase secretion of GnRH [54, 55].  During the 
summer months when day length is long, melatonin secretion is negatively inhibited [54].  This 
inhibition is enacted primarily by non-visual light-sensitive ganglia within the retina. 
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Darkness and light are perceived by the retina. The retina receives more excitatory 
stimulation when periods of light are long; this stimulation is transmitted to the suprachiasmatic 
nucleus region (SCN) of the hypothalamus via the retinohypothalamic tract, (as reviewed by 
[56]).  The SCN transmits the stimulus to the preganglionic neurons of the superior cervical 
ganglion.  This causes postganglionic neurons to fire and excite inhibitory neurons in the pineal 
gland which inhibit pinealocytes from secreting melatonin.  Decreased melatonin secretion 
causes the hypothalamus to be more sensitive to the negative feedback of estradiol; the 
hypothalamus responds by secreting less GnRH, and the pituitary by secreting less LH [53].  
Circulating progesterone concentrations decrease after the last luteal phase of the breeding 
season.  Remarkably, secretion of FSH remains robust during the transition to anestrus; however, 
it appears that the ovary becomes less sensitive to gonadotropin stimulation [57].  Ewes still 
develop follicles on the ovary during the anestrous period, however, emergence of follicular 
waves does not result in higher levels of circulating estrogen [57]. 
As the hours of light begin to shorten during the months of autumn, the retina receives 
fewer excitatory stimuli.  Negative inhibition of pinealocytes diminishes, and allows increased 
secretion of melatonin.  In addition, the hypothalamus becomes less sensitive to the negative 
feedback of estradiol, and cyclicity resumes. 
When transitioning into the breeding season, the first ovulation is not accompanied by 
estrous behavior.  Progesterone priming of the hypothalamus is necessary before estrous 
behavior will be displayed.  The CL that results from the first ovulation of the breeding season is 
often sub-normal, but is sufficient to prime the hypothalamus, and estrous behavior is displayed 
before the second ovulation. 
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Various protocols have been established to stimulate fertile ovulations during the 
transition to anestrous or anestrous periods of sheep.  Once of the most widely used protocols in 
Australia and New Zealand uses a controlled internal drug releasing (CIDR; EAZI-BREED 
CIDR protocol) progesterone insert followed by injection with PMSG (400-500 IU).  The CIDR 
is inserted for 14 days to simulate a luteal phase, prime the hypothalamus, and increase GnRH 
pulse frequency.  The PMSG is given on day 14 at CIDR removal; PMSG functions as surrogate 
gonadotropin support for growing follicles, similar to that of FSH, but with longer half-life in 
circulation.  This protocol induces estrus and fertile ovulations about 54 hours after CIDR 
removal/PMSG injection. 
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CHAPTER 2 - EXPRESSION OF FOLLICLE STIMULATING 
HORMONE RECEPTOR VARIANTS DURING THE ESTROUS 
CYCLE OF SHEEP 
Introduction 
For successful reproduction to occur, follicles must develop and grow within the ovary.  
Antral follicle growth is regulated largely by the pituitary gonadotropins follicle stimulating 
hormone (FSH) and luteinizing hormone (LH).  In order for gonadotropins to exert their effects, 
the appropriate receptors must be present at the correct time.  Follicle stimulating hormone 
receptor (FSHR) is detectable soon after follicle formation in sheep [13].  Several alternatively 
spliced FSHR mRNA variants have been identified in sheep [5, 7, 13, 50].  Each splice variant 
has a unique exon structure which may dictate receptor coupling to signaling molecules.  
Messenger RNA for the G protein-coupled form of the FSHR (hereafter referred to as FSHR-1) 
was first described in the rat in 1990 [6] and in the sheep in 1993 [5].  Sheep FSHR-1 mRNA is 
2431 base pairs (bp) in length, and consists of 10 exons. Once translated, FSHR-1 is capable of 
activating several intracellular signaling pathways, but cAMP/PKA is the most commonly 
described pathway (as reviewed by [58]).  The FSHR-1 is important for granulosa cell (GC) 
differentiation and hormone production, as well as GC proliferation (as reviewed by [59]).  Other 
identified splice variants include FSHR-2 (dominant negative receptor) and FSHR-3 (growth 
factor type-1 receptor).  
 The exon structure of FSHR-2 is similar to that of FSHR-1, except that FSHR-2 has a 
truncated exon 10 spliced to exon 11 [50].  The truncation in exon 10 is thought to affect 
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receptor signaling.  Although FSHR-2 has been shown to bind FSH with high affinity, 
downstream signaling did not occur [8].  In fact, when FSHR-2 and FSHR-1 were cotransfected 
into HEK 293 cells and treated with FSH, only a small increase in intracellular cAMP was 
detectable, in contrast to the large increase normally caused by FSHR-1.  Thus, FSHR-2 
appeared to attenuate the actions of FSHR-1, leading the authors to conclude that FSHR-2 acts as 
a dominant negative form of the FSHR [8]. 
Exons 1-8 of FSHR-3 are identical to that of FSHR-1; however, FSHR-3 lacks exons 9 
and 10, and is spliced to exon 11 [7, 9].  In contrast to FSHR-1, FSHR-3 is thought to act in a 
cAMP-independent fashion.  When stimulated by FSH, it has been shown to activate a mitogen-
activated protein kinase (MAPK) pathway, specifically the extracellular-regulated kinase (ERK) 
signaling cascade [52].  The ERK cascade is involved in cell proliferation and is regulated by 
Ras; activation of the ERK cascade is Ca2+ dependent.  When Touyz et al. (2000) transfected 
HEK 293 cells with FSHR-3, treatment with FSH resulted in a dramatic increase in Ca2+ [51].  
The significance of these findings relates to the increases in cell proliferation observed shortly 
after calcium influx and activation of the ERK signaling cascade.  These studies illustrate that 
FSH can stimulate cell proliferation directly through FSHR-3. 
In the cow, FSHR transcripts containing exon 11 are more highly expressed in cohort and 
subordinate follicles compared to dominant follicles.  However, FSHR transcripts containing 
exon 10 are more highly expressed in cohort and dominant follicles than in subordinate follicles 
during the estrous cycle [60, 61].  Based on those findings, we postulated that in sheep, 
transcripts in addition to FSHR-1 may act in a concerted fashion to cause follicular growth and 
atresia.  The aim of these experiments was to determine the expression patterns of FSHR variants 
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during the estrous cycle under normal physiological conditions, and to determine if treatment 
with PMSG altered expression patterns. 
Materials and Methods 
Animals and Sample Collection 
All animal procedures were approved by the Kansas State University Animal Care and 
Use Committee (IACUC #2735).  Ewes were group housed outside at the KSU Sheep Unit in a 
south-facing lean-to barn and were exposed to natural lighting and temperature (39° 12′ 22″ N, 
96° 35′ 12″ W).  Ewes had free access to water and were fed a maintenance diet of grass hay and 
2 pounds/head/day of a grain supplement (87% DM; 14% CP; 85% TDN).  Ewes were 
transported from the KSU Sheep Unit to the KSU Diagnostic Lab for euthanasia.  When ewes 
were loaded onto the trailer, blood samples were collected via jugular venipuncture and placed 
on ice until refrigeration at 4°C for 24 hours.  Serum was separated by centrifugation at 1500xg 
for 20 minutes at 4°C.  Serum was decanted into a 5 ml polypropylene tube, capped and stored at 
-20°C until assay.  Time from loading ewes to euthanasia was less than 1 hour. Ewes were 
euthanized by intravenous overdose (90mg/kg) of sodium pentobarbital. 
Experiment 1:  Eight mature cycling (2-8 years of age) Suffolk-cross ewes were allowed 
to come into estrus naturally.  Estrous cycle length was monitored through 3 cycles before 
harvesting ovaries at the end of the breeding season, starting on January 23, 2009, and ending on 
February 3, 2009.  Cyclicity was monitored using a HeatWatch® detection system (Denver, CO) 
and two vasectomized rams.  Onset of estrus was defined as the beginning of the period that a 
ewe was receptive to mounting by the ram.  After a HeatWatch® transmitter was activated by a 
ram, estrus behavior was visually confirmed.  Ewes were euthanized 24 (n=3), 36 (n=3), or 48 
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(n=2) hours after onset of estrus.  Ovaries were harvested and placed on ice before transport to 
Weber Hall for evaluation.  Left and right ovaries of each ewe were kept separate until 
photographed and all ovarian structures were measured (to the nearest 0.5 mm) and recorded.  
Ovarian structures were measured with a transparent ruler from the external surface of the ovary.  
All visible follicles were aspirated using 1cc syringes and 20 gauge needles.  Each follicle was 
aspirated such that the needle was inserted, follicular fluid was pulled into the syringe and then 
pushed back into the same follicle three times before removing the needle and moving to the next 
follicle.  A new syringe and needle were used for each ewe and each follicle size class.  Aspirates 
were pooled in 1.5 ml microcentrifuge tubes according to follicular diameter: small (≤ 2.0 mm), 
medium (2.1-4.0 mm) large (4.1-6.0 mm) and preovulatory (≥ 6.1 mm).  Follicular fluid and 
granulosa cells were separated by centrifugation at room temperature for two minutes at 2300xg.  
Follicular fluid was removed and stored at -20°C for estrogen and progesterone assays. 
Granulosa cell pellets were resuspended in 500 µl ice-cold Dulbecco’s Phosphate 
Buffered Saline (PBS; Invitrogen, Carlsbad, CA), then centrifuged at room temperature for one 
minute at 2300xg. The PBS was aspirated and discarded and the granulosa cell pellets were 
resuspended in 1 ml TRIzol® reagent (Invitrogen) and frozen at -20°C until all samples were 
collected.  Time between ovary harvest and placing granulosa cells in TRIzol® reagent did not 
exceed 2 hours. 
Experiment 2:  Seven mature (ages 1-8) Suffolk-cross ewes received controlled internal 
drug-releasing (CIDR; EAZI-BREED™ CIDR®, Pfizer New Zealand, Mt. Eden, Auckland) 
progesterone inserts for 14 days (beginning on February 9, 2009), followed by treatment (n=3) 
with pregnant mare serum gonadotropin (PMSG, 500IU; SIGMA, St. Louis, MO), or no PMSG 
(n=4; CIDR only).  Ewes were euthanized 24 (n=4; 2 CIDR-only, 2 PMSG-treated), or 36 (n=3; 
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2 CIDR-only, 1PMSG treated) hours after CIDR removal.  All other procedures are the same as 
for Experiment 1. 
RNA Isolation and DNase Treatment 
RNA was isolated from samples using TRIzol® reagent according to the manufacturer’s 
instructions (protocol in Appendix A).  The RNA pellet was washed with 75% EtOH and 
resuspended in 15 µl preheated (65°C) nuclease-free water (Ambion®, Austin, TX).  All RNA 
extracts were treated with TURBO DNA-free™ (DNase; Ambion®) according to the 
manufacturer’s instructions (protocol in Appendix A) to remove any genomic or other cellular 
DNA and stored at -20°C. 
Reverse Transcription – Polymerase Chain Reaction 
Total RNA (100 ng) was used as starting template for RT-PCR.  Some samples with low 
(≤ 50ng/µl) concentrations of total RNA initially failed to produce consistent real-time PCR 
products.  Total RNA from those samples was then reverse-transcribed using 200 or 300 ng 
RNA.  Samples that required ≤ 0.4 µl total RNA to be pipetted were diluted 1:10, and 10 times 
the diluted amount was used, contributing 8 µl of a 20 µl total reaction volume.  Total RNA was 
reverse-transcribed using SuperScript™ III First-Strand Synthesis SuperMix (Invitrogen), 
according to the manufacturer’s instructions (protocol in Appendix A).  Conditions were as 
follows for reverse transcription:  25°C hold for 25 minutes, 42°C for 50 minutes, 85°C for 5 
minutes.  At the end of the reverse-transcription reaction, samples were placed on ice for at least 
1 minute.  To remove template RNA, 1 µl RNase H was added to each sample and samples were 
incubated at 37°C for 20 minutes.  Reactions were stored at -20°C until used for qPCR. 
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Real-Time Polymerase Chain Reaction 
Real-time PCR was performed using an ABI 7500 Fast machine (Applied Biosystems, 
Foster City, CA) with the following parameters:  50°C for 2 min hold, 95° for 2 min hold, 40 
cycles of:  95°C for 15 sec, 60°C for 30 sec.  Platinum® SYBR® Green qPCR SuperMix-UDG 
(Invitrogen™, Carlsbad, CA) was used at 10 µl per well; forward and reverse primers were used 
at 250 nM concentrations, cDNA template was diluted in 5 µl total volume using nuclease-free 
water, and nuclease-free water was used to bring the final reaction volume to 20 µl.  Melt-curve 
analysis was performed on all samples after amplification, by heating products to 95°C and 
plotting the derivative of the reporter (fluorescence) and temperature at which products denature 
(separation of products prevents fluorescence).  All primers were designed using Primer 
Express® 3.0 software (Applied Biosystems) and synthesized by Applied Biosystems.  Beta-
Actin was used as an internal standard.  Primers used to detect (Table 2.1) FSHR-1, FSHR-2, and 
FSHR-3 were designed to amplify each variant specifically, based on submitted nucleotide 
sequences of each variant (Figures 2.1-2.3). 
           
Target 
 
Accession No. 
 
Primer Name 
 
Sequences 5’ to 3’ 
Primer 
(bp) 
Amplicon 
(bp) 
Beta-Actin NM_001009784 oBeta-Actin Forward 
oBeta-Actin Reverse 
GTCATCACCATCGGCAATGA 
CGTGAATGCCGCAGGATT 
20 
18 
 
88 
 
FSHR-1 L07302 oExon 10-1 Forward 
oExon 10-1 Reverse 
CATTCACTGCCCACAACTTTCATC 
TGAGTGTGTAATTGGAACCATTGGT 
24 
25 
 
84 
 
FSHR-2 NM_001009289 oExon 10/11-1 Forward 
oExon 10/11-1 Reverse 
CAGGAACTTCCGCAGGGATT 
TGATTGCAGATGAGCCCAACA 
20 
21 
 
72 
 
FSHR-3 L12767 oExon 8/11-0 Forward 
oExon 8/11-0 Reverse 
CAGTAATTTGGAAGAACTGCCTAATG 
AACAGTGCAGCAGTGGAGACA 
26 
21 
 
80 
 
LHR L36329 oLHR Forward 
oLHR Reverse 
AGATTGCTAAGAAAATGGCAGTCCTCT 
GCAGCTGAGATGGCAAAGAAAGAGA 
28 
25 
 
82 
 
 
Table 2.1.  Description of primers used for quantitative real-time PCR.
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Figure 2.1.  Nucleotide sequence and exon structure for FSHR-3.   
The FSHR-3 mRNA(accession No. L12767) consists of exons 1-8 spliced to exon 11, and is 
1091 nucleotides (nt) in length.  Exon numbers and nt per exon are denoted in the colored boxes 
along the left side of the figure.  Primers for real-time PCR, designed with Primer Express® 3.0 
software, were constructed to span exons 8 and 11 so that only FSHR-3 and neither FSHR-2 
(which contains exons 9 and 10) nor FSHR-1 (which lacks exon 11) would be amplified.   
Annealing sites for the exon 8/11 primer pair are bold and underlined.  The expected amplicon 
would start at nt-658 and extend through nt-728 (80 nt in length). 
25 
 
 
Figure 2.2.  Nucleotide sequence and exon structure for FSHR-2. 
The FSHR-2 mRNA (accession No. NM_001009289) consists of exons 1-9 and a truncated exon 
10 spliced to exon 11, and is 2428 nucleotides (nt) in length.  Exon numbers and nt per exon are 
denoted in the colored boxes along the left side of the figure.  Primers for real-time PCR, 
designed with Primer Express® 3.0 software, were constructed to span exons 10 and 11 so that 
only FSHR-2 and neither FSHR-3 (which lacks exons 9 and 10) nor FSHR-1 (which lacks exon 
11) would be amplified.  Annealing sites for the exon 10/11 primer pair are bold and underlined.  
The expected amplicon would start at nt-2011 and extend through nt-2082 (72 nt in length). 
26 
 
 
Figure 2.3.  Nucleotide sequence and exon structure for FSHR-1.   
The FSHR-1 mRNA (accession No. L07302) consists of exons 1-10, and is 2431 nucleotides (nt) 
in length.  Exon numbers and nt per exon are denoted in the colored boxes along the left side of 
the figure.  Primers for real-time PCR, designed with Primer Express® 3.0 software, were 
constructed to reside within the latter part of exon 10 so that only FSHR-1 and neither FSHR-2 
(which is truncated at nt 2045 of exon 10) nor FSHR-3 (which lacks exons 9 and 10) would be 
amplified.  Annealing sites for the exon 10 primer pair are bold and underlined.  The expected 
amplicon would start at nt-2097 and extend through nt-2180 (84 nt in length). 
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RIA 
Duplicate aliquots (50 µl) of serum were assayed for progesterone concentration, as 
described and validated previously [62].  Sensitivity of the assay was 3.5 pg/tube and the mean 
intra- and inter-assay coefficients of variation (CV) were 4.75% and 4.55%, respectively.  
Duplicate aliquots (200 µl total volume) of follicular fluid were assayed without extraction for 
estradiol and progesterone, using previously described and validated assays [63, 64] (protocols in 
Appendix A).  Briefly, for estradiol evaluation, follicular fluid from small and medium-sized 
follicles was diluted 1:100 and follicular fluid from large and preovulatory follicles was diluted 
1:500 prior to assay.  Estradiol concentration was determined using a double antibody kit from 
Siemens Medical Solutions Diagnostics (Deerfield, IL).  Sensitivity of the assay was 0.02 
pg/tube and the mean intra-assay CV was 1.6%.  Progesterone concentrations were determined 
using Coat-A-Count antibody coated tubes from Siemens Medical Solutions Diagnostics.  For 
progesterone evaluation, follicular fluid from all follicle sizes was diluted 1:50.  Sensitivity of 
the assay was 0.012 ng/tube and the mean intra-assay CV was 9.35%. 
Statistical Analysis 
Relative Expression (2.0-∆Ctx1000) values were used for statistical analysis of real-time 
PCR data.  Data were analyzed with SAS 9.1 software (SAS Institute, Cary, NC) using Proc 
Mixed and least squared means.  Both experiments had a completely randomized design with a 
split-plot; for both experiments, the split-plot has treatments in a 2 (follicle size) x 4 (gene) 
factorial.  The ANOVA models included all treatment factor main effects and interactions; ewe 
was included as a random effect.  Normality of residuals was tested and data transformed if 
necessary.  For Experiment 1, the whole-plot treatment factor is hour and experimental unit is 
ewe.  Gene expression in preovulatory follicles was analyzed separately because this size was 
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only present in the 24 hour group.  Untransformed data are presented as least squared means of 
relative expression, ± SEM.  For Experiment 2, the whole-plot treatments are in 2 (hour) x 2 
(treatment) factorial and the whole- plot experimental unit is ewe.  Data were (natural) log 
transformed to achieve normality.  After least squared means were calculated, they were back-
transformed (by exponentially raising the transformed mean values).  Confidence intervals for 
the transformed means were calculated so new standard errors could be assigned.  Back-
transformed data are presented as least squared means of relative expression, ± SEM.  Data for 
the large follicle size class could not be statistically analyzed, as this size was only found in one 
ewe from the 24 hour PMSG group and one ewe from the 36 hour control group.  Therefore, 
relative expression from the large follicle group are presented as raw data. 
Analysis of Techniques 
RNA Quantitation 
After DNase treatment, RNA was quantified with a Nanodrop 1000 Spectrophotometer 
(protocol in Appendix A) to determine RNA quantity at 260 nm.  All RNA was diluted 1:3 
before quantitation (2 µl RNA was diluted in 4 µl nuclease-free water) and analyzed in duplicate 
with the Nanodrop; DNase buffer was used as the blank calibrator.  The quantity of RNA in each 
sample was confirmed at the same time that quality of the RNA was examined using an Agilent 
2100 Bioanalyzer with an Agilent 6000 Nano Kit (Agilent Technologies, Waldbronn, Germany).  
The Nano chip was prepared according to the manufacturers instructions (protocol in Appendix 
A).  Briefly, 1 µl total RNA (undiluted) and marker (5 µl; marker is used to equalize loading; 
6µL total reaction volume) was loaded into a gel-dye matrix in an Agilent 6000 Nano chip 
(Agilent Technologies).  A 6000 nucleotide (nt) RNA ladder (6 µl) was used for size 
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comparison; each chip (12 samples) was electrophoresed using the Agilent 2100 Bioanalyzer and 
the eukaryotic total RNA program settings. 
 
Figure 2.4.  Comparison of quantitation methods after extraction of total RNA—
Experiment 1. 
Granulosa cells were collected from ewes 24, 36 or 48 hours after the onset of estrus and pooled 
according to follicle diameter:  small (≤ 2.0 mm), medium (2.1-4.0 mm) and preovulatory 
(preov; ≥ 6.1 mm).  Total RNA was extracted with TRIzol reagent and then subjected to DNase 
treatment (Turbo DNA-free; used for blank measurement).  Total RNA was quantified by 
loading 1 µl total RNA (undiluted) onto an Aglient 6000 Nano chip and reading with an Agilent 
2100 Bioanalyzer (gray bars), which uses fluorescence to quantify RNA.  Total RNA was also 
quantified by loading duplicate aliquots (1.3 µl) of diluted (1:3) onto the Nanodrop 1000 
Spectrophotometer (black bars), which uses absorbance at 260 nm to quantify RNA.  Overall, 
Nanodrop concentrations were higher than Bioanalyzer concentrations, but the two methods 
were correlated (R=.83). 
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Figure 2.5.  Comparison of quantitation methods after extraction of total RNA—
Experiment 2. 
Granulosa cells were collected from ewes 24 or 36 hours after CIDR removal and pooled 
according to follicle diameter:  small (≤ 2.0 mm), medium (2.1-4.0 mm) and  large (4.1-6.0 mm).  
Total RNA was extracted with TRIzol reagent and then subjected to DNase treatment (Turbo 
DNA-free; used for blank measurement).  Total RNA was quantified by loading 1 µl total RNA 
(undiluted) onto an Aglient 6000 Nano chip and reading with an Agilent 2100 Bioanalyzer (gray 
bars), which uses fluorescence to quantify RNA.  Total RNA was also quantified by loading 
duplicate aliquots (1.3 µl) of diluted (1:3) onto the Nanodrop 1000 Spectrophotometer (black 
bars), which uses absorbance at 260 nm to quantify RNA.  Overall, Nanodrop concentrations 
were higher than Bioanalyzer concentrations, but the two methods were correlated (R=.79). 
RNA Quality 
The RNA quality was assessed on 3-23-09 and 3-24-09 (in the same assay that measured 
quantity) with the Agilent 2100 Bioanalyzer (Figure 2.6).  One sample, (from Ewe 11; 36 hour) 
containing total RNA from one preovulatory-sized follicle was thrown out after failing to 
amplify any gene (other than β-actin), in 10 duplicate real-time PCR reactions.  The RNA quality 
of this sample was later shown to be poor (Figure 2.6 C, lane 6).  One sample containing medium 
follicles from Ewe 4 (48 hour; n=3 follicles) had an estrogen to progesterone ratio of 2.0, and 
could therefore be considered a pool of healthy follicles.  Interestingly, both FSHR-2 and LHR 
were not amplified in that sample (even after 4 attempts).  RNA quality for that sample was 
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shown to be poor (Figure 2.6, B, lane 11), but two variants, FSHR-1 and FSHR-3, were still 
amplified. 
 
 
Figure 2.6.  Quality assessment of total RNA from sheep granulosa cells. 
Total RNA (1 µl) and marker (5 µl; marker is used to equalize loading and is seen as the bright 
green band in each lane; 6µL total reaction volume) was loaded into a gel-dye matrix in an 
Agilent 6000 Nano chip and electrophoresed using the Agilent 2100 Bioanalyzer with the 
eukaryotic total RNA program settings.  A 6000 nucleotide (nt) RNA ladder (6 µl) was used for 
size comparison (Lane L, each panel) Ribosomal RNA 18S and 28S bands appear at 1800 and 
4000 nts, respectively.  Panel A) Samples from Experiment 2: all samples have 18- and 28S 
bands with the exception of Lane 12.  Panel B) Samples from Experiment 2, lanes 1-6; samples 
from Experiment 1, lanes 7-12; samples in lanes 1, 4, 5 and 7 are of good quality; samples in 
lane, 9, 10, and 12 have faint 18S bands; samples in lanes 2, 3, 6, 8 and 11 have degraded.  Panel 
C) Samples from Experiment 1:  Sample in lane 11 is of good quality; samples in lanes 2, 3, 4, 7 
and 8, have 18S bands and some faint 28S bands; samples in lane 5 and 6 have low RNA 
quantity and thus, quality is difficult to assess; samples in lanes 1, 9, 10, and 12 have degraded.  
Panel D) Samples from Experiment 1, lanes 1-4; lanes 6-8, reruns; samples in lanes 1, 3, 4, 6, 7 
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and 8 are good quality; samples in lanes 2 and 5 are degraded.  Quality was assessed more than 
one month after quantitative PCR (qPCR) was completed; samples appeared to degrade over 
time, as Panel A samples were collected more recently than panel C samples.  Quality of RNA 
was assumed to be similar to that of panel A, lane 11 at the time of qPCR. 
Agarose Gel Electrophoresis 
Each FSHR variant template amplified by real-time PCR was examined by agarose gel 
electrophoresis (protocol in Appendix A) to examine amplicon size (Figure 2.7, F).  Real-time 
PCR products (30 µl) and 4 µl sample buffer were loaded into a 1.5% agarose gel.  A 100 bp 
DNA ladder standard (6 µl; New England Biolabs, Beverly, MA) and 4 µl sample buffer was 
used for size reference.  Samples were electrophoresed for 105 volt hours (1.5 hours x 70 volts) 
then visualized with UV light.  Bands were visible for each primer set at the anticipated size. 
Melting Curve Analysis 
Melting curves were generated for each real-time PCR reaction; examples of melting 
curves for each primer set are shown in Figure 2.7, A-E, and each appears to show amplification 
of only one product per primer set. 
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Figure 2.7.  Representative melt-curve analysis of primer sets and amplicon size. 
Total RNA from sheep granulosa cells was DNase treated and reverse-transcribed, then 
subjected to quantitative PCR with SYBR Green dye.   A-E) Representative melting curves for 
each primer set (non-template controls for each set appear at bottom left corner of each graph) 
show only one peak and thus amplification of only one product.  Melting temperature of target 
amplicons ranged from 78.51-84.22°C, and from 62.06-63.83°C for non-template controls.  F) 
Real-time PCR products for FSHR variants were electrophoresed in a 1.5% agarose gel with 0.6 
µl ethidium bromide.  Lane 1, 100 base pair (bp) DNA ladder standard, white arrow indicates the 
100 bp marker; lane 2, FSHR-1; lane 3, FSHR-2; lane 4 FSHR-3.  Each reaction produced only 
one band at the expected size of approximately 84, 72, and 80 bp, respectively.  Collectively, 
evidence provided in panels A-F illustrates that real-time PCR primers were amplifying only the 
correct targets. 
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Results 
Relative gene expression was determined for both experiments.  Primer efficiencies 
ranged from 85 to 100%.  Primer efficiencies under 95% were corrected to 100% so that 
comparisons between genes could be made.  For Experiment 1, when comparing all FSHR 
variants and LHR within a follicle class size, FSHR-3 was more highly expressed than FSHR-1 
in medium follicles (p < 0.01; Figure 2.8, B), and tended to be higher in small follicles (p=0.09).  
Relative expression of FSHR-3 was higher than FSHR-2 in small and medium follicles (p < 
0.01; Figure 2.8, A).  In preovulatory follicles, LHR expression increased dramatically and was 
higher than all FSHR variants (p < 0.05); expression of FSHR variants was numerically lower 
than in small and medium follicles (Figure 2.8 C). 
When comparing expression of each variant between small and medium follicles, neither 
FSHR-1 nor FSHR-2 was differentially expressed (p=0.34 and 0.42, respectively; Figure 2.9, A, 
B); however, FSHR-3 expression was higher in medium than in small follicles (p < 0.01; Figure 
2.9, C). Relative expression of LHR was essentially undetectable in small follicles and very low, 
on average, in medium follicles (p=0.85; Figure 2.9, D). 
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Figure 2.8.  Expression of gonadotropin receptors within different sized sheep follicles—
Experiment 1. 
Granulosa cells were collected from small (≤ 2.0 mm), medium (2.1-4.0 mm) and preovulatory 
(≥ 6.1 mm;*only found in the 24 hour group) follicles.  After total RNA was extracted, it was 
subjected to reverse transcription and quantitative PCR.  Data are expressed as least squared 
means of relative expression (2-∆Ct x1000; arbitrary units) ± SEM.  Bars within graphs with 
differing superscripts are different (p ≤ 0.05).  Expression of FSHR-1 (white bars), FSHR-2 
(light gray bars), FSHR-3 (dark gray bars), and LHR (black bars) are compared within a follicle 
size class.  Panel A) Relative expression of FSHR-3 was higher than FSHR-2 and LHR, and 
tended to be higher than FSHR-1(*p=0.09) in small follicles.  Panel B) Relative expression of 
FSHR-3 was higher than other variants and LHR in medium follicles.  Relative abundance of 
mRNA for FSHR-1 and FSHR-2 did not differ, but both were more highly expressed than LHR.  
Panel C) Relative expression of LHR was the highest in preovulatory follicles, while FSHR-1, 
FSHR-2, and FSHR-3 did not differ. 
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Figure 2.9.  Expression of gonadotropin receptors across different sized sheep follicles—
Experiment 1. 
Granulosa cells were collected from small (≤ 2.0 mm; white bars) and medium (2.1-4.0 mm; 
gray bars) follicles.  After total RNA was extracted, it was subjected to reverse transcription and 
quantitative PCR.  Data are expressed as least squared means of relative expression (2-∆Ct x1000; 
arbitrary units) ± SEM.  Bars within graphs with differing superscripts are different (p < 0.01).  
Panels A, B, and D) Relative expression of FSHR-1, FSHR-2, and LHR did not significantly 
differ in small versus medium follicles.  Panel C) Relative expression of FSHR-3 was higher in 
medium than small follicles.  Overall, FSHR-3 expression was the only transcript that differed 
between small and medium follicles. 
Experiment 2 real-time PCR results were somewhat different from those in Experiment 1.  
When comparing all transcripts within a follicle size, FSHR-1 and FSHR-3 were more highly 
expressed than FSHR-2 and LHR in small and medium follicles (p < 0.01; Figure 2.10 A,B).  
When comparing relative expression of each transcript in small or medium follicles, expression 
of FSHR variants was numerically higher in small than medium follicles (p > 0.2); expression of 
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LHR was higher in small than medium follicles (p < 0.05; Figure 2.11, A-D).  Relative 
expression of LHR was higher (p < 0.05) in medium than in small follicles (Figure 2.11, D). 
 
Figure 2.10.  Expression of gonadotropin receptors within different sized sheep follicles—
Experiment 2. 
Granulosa cells were collected from small (≤ 2.0 mm) and medium (2.1-4.0 mm) follicles.  After 
total RNA was extracted, it was subjected to reverse transcription and quantitative PCR.  Data 
are expressed as least squared means of relative expression (2-∆Ct x1000; arbitrary units) ± SEM.  
Bars within graphs with differing superscripts are different (p < 0.01).  Expression of FSHR-1 
(white bars), FSHR-2 (light gray bars), FSHR-3 (dark gray bars), and LHR (black bars) are 
compared within a follicle size class.  Relative expression of FSHR-1 and -3 was higher than 
FSHR-2 and LHR in small follicles and medium follicles (Panels A and B). 
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Figure 2.11.  Expression of gonadotropin receptors across different sized sheep follicles—
Experiment 2. 
Granulosa cells were collected from small (≤ 2.0 mm; white bars) and medium (2.1-4.0 mm; 
gray bars) follicles.  After total RNA was extracted, it was subjected to reverse transcription and 
quantitative PCR.  Data are expressed as least squared means of relative expression (2-∆Ct x1000; 
arbitrary units) ± SEM.  Bars within graphs with differing superscripts are different (p < 0.05).  
Panel A, B, C) Relative expression of FSHR-1, FSHR-2, and FSHR-3 did not differ in small 
versus medium follicles, although expression was numerically higher in small than medium 
follicles.  Panel D) Relative expression of LHR was higher in medium than small follicles.  
Overall, LHR expression was the only transcript that differed between small and medium 
follicles. 
When treatment (control versus 500 IU PMSG) and time from CIDR removal to 
euthanasia (24 versus 36 hours) were compared, no differences in gene expression in different 
follicles sizes were found (Figures 2.12 and 2.13).  Overall, relative expression of FSHR-3 was 
numerically (but not statistically) higher than other transcripts, regardless of time, treatment, or 
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follicle size (in the only available comparisons that could be made:  small versus medium 
follicles). 
 
 
Figure 2.12.  Expression of gonadotropin receptors at 24 hours after CIDR removal within 
small and medium sheep follicles—Experiment 2. 
All ewes were treated with CIDRs for 14 days.  At CIDR removal, ewes received either no 
treatment (n=2 control; 24 CTRL), or 500 IU PMSG (n=2; 24 PMSG) and were euthanized 24 
hours later.  Granulosa cells were collected from small (≤ 2.0 mm) and medium (2.1-4.0 mm) 
follicles.  After total RNA was extracted, it was subjected to reverse transcription and 
quantitative PCR.  Data are expressed as least squared means of relative expression (2-∆Ct x1000; 
arbitrary units) ± SEM.  Expression of FSHR-1, FSHR-2, FSHR-3 and LHR are compared 
between treatments within a follicle size class.  Relative expression of FSHR-3 was numerically 
higher than other transcripts, but was not statistically different. 
m
R
N
A
 E
x
p
re
ss
io
n
 R
e
la
ti
v
e
 t
o
 β
-a
ct
in
 
Small Medium 
40 
 
 
 
 
Figure 2.13.  Expression of gonadotropin receptors at 36 hours after CIDR removal within 
small and medium sheep follicles—Experiment 2. 
All ewes were treated with CIDRs for 14 days.  At CIDR removal, ewes either received no 
treatment (n=2 control; 36 CTRL), or 500 IU PMSG (36 PMSG*; *relative expression values 
from one ewe) and were euthanized 36 hours later.  Granulosa cells were collected from small (≤ 
2.0 mm) and medium (2.1-4.0 mm) follicles.  After total RNA was extracted, it was subjected to 
reverse transcription and quantitative PCR.  Data are expressed as least squared means of relative 
expression (2-∆Ct x1000; arbitrary units) ± SEM.  Expression of FSHR-1, FSHR-2, FSHR-3 and 
LHR are compared between treatments within a follicle size class.  Relative expression of FSHR-
3 was numerically higher than other transcripts, but was not statistically different. 
When large follicle gene expression was evaluated, only raw data could be reported due 
to sample numbers.  Relative expression of LHR appeared to increase in small compared to 
medium follicles (Figure 2.14).  Expression of FSHR-2 was numerically lower than both FSHR-
1 and FSHR-3. 
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Figure 2.14.  Expression of gonadotropin receptors within large sheep follicles—
Experiment 2. 
All ewes were treated with CIDRs for 14 days.  At CIDR removal, ewes received either no 
treatment or 500 IU PMSG and were euthanized 24 or 36 hours later.  Granulosa cells were 
collected from large (4.1-6.0 mm; only found in two ewes) follicles.  After total RNA was 
extracted, it was subjected to reverse transcription and quantitative PCR.  Because only two ewes 
had follicles of the large class, no statistical analysis could be performed on this size.  Data are 
presented as means (of duplicate wells) of relative expression (2-∆Ct x1000; arbitrary units).  
Relative expression of FSHR-3 appeared to be higher than other transcripts in Ewe 8018.  As 
with Experiment 1, LHR expression appeared to increase with increasing follicle size. 
Overall, relative expression of FSHR-2 remained lower than FSHR-1 or FSHR-3 in both 
experiments.  Generally, FSHR-3 expression was numerically higher than other variants, but 
statistically similar to expression of FSHR-1.  Relative expression of LHR was low in small and 
medium follicles, but increased in both large and preovulatory follicles. 
Follicular fluid estrogen and progesterone concentrations were determined using RIA.  
For Experiment 1, estradiol concentrations were consistently lower than progesterone (Figure 
2.15); consequently, only one estradiol to progesterone ratio exceeded 1.0.  That sample, (Ewe 4, 
48 hour; n=3 medium follicles) had ratio of 2.0, and could therefore be considered a pool of 
healthy follicles. 
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Figure 2.15.  Estradiol and progesterone concentrations in follicular fluid from different-
sized sheep follicles—Experiment 1. 
Follicular fluid was pooled according to follicle diameter:  small (≤ 2.0 mm), medium (2.1-4.0 
mm) and preovulatory (preov; ≥ 6.1 mm).  After granulosa cells were separated by 
centrifugation, duplicate aliquots (200 µl total volume) of follicular fluid were analyzed by RIA 
without extraction.  Progesterone concentrations were consistently higher than estradiol in small, 
medium and preovulatory follicular fluid pools.  Data are expressed as mean ± SEM. 
Estradiol concentrations from small follicle pools averaged 0.77 ng/ml.  In small follicle 
pools, follicular fluid from Ewe 11 (36 hour; n=14 follicles) had the lowest (0.07 ng/ml) estradiol 
concentration while Ewe 16 (24 hour; n=3 follicles) had the highest (2.26 ng/ml) estradiol 
concentration.  Estradiol concentrations for medium follicles averaged 2.53 ng/ml. In medium 
follicle pools, follicular fluid from Ewe 6 (24 hour; n=7 follicles) had the lowest (0.05 ng/ml) 
estradiol concentration, while Ewe 4 (48 hour; n=3 follicles) had the highest (13.60 ng/ml) 
concentration.  Estradiol in preovulatory follicles averaged 3.18 ng/ml.  Preovulatory follicles 
were only present in the 24 hour group, with Ewe 12 (24 hour; n=2 follicles) having the lowest 
(0.91 ng/ml) estradiol concentration and Ewe 16 (24 hour; n=2 follicles) having the highest (7.28 
ng/ml) concentration.  Mean progesterone concentration in small follicles was 7.61 ng/ml and 
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ranged from 1.61-10.97 ng/ml.  Progesterone concentration in medium follicles averaged 4.18 
ng/ml and ranged from 1.38-7.21 ng/ml.  Preovulatory follicles had the highest mean 
progesterone concentration at 66.74 ng/ml, ranging from 43.70-90.29 ng/ml. 
The E:P ratio was compared to relative gene expression of each transcript.  Correlation 
values for Experiment 1 are presented in Figure 2.16.  Correlation between E:P and expression 
was the highest for FSHR-2 in small follicles (R=0.4), although FSHR-2 was still the least 
expressed transcript.  In medium follicles, the highest correlation was between E:P and LHR 
(R=0.51). 
 
Figure 2.16.  Correlation between estradiol to progesterone ratio and gene expression in 
small and medium sheep follicles—Experiment 1. 
Follicular fluid was pooled according to follicle diameter:  small (≤ 2.0 mm) and medium (2.1-
4.0 mm).  After granulosa cells were separated by centrifugation, duplicate aliquots (200 µl total 
volume) of follicular fluid were analyzed by RIA without extraction.  Estradiol and progesterone 
concentrations were determined for each sample, and the ratio of estradiol to progesterone was 
calculated.  The FSHR-2 variant had the highest correlation (R=0.4) to the E:P ratio compared to 
other FSHR variants.  The E:P was inversely correlated to LHR expression in small follicles (R=-
0.41), and FSHR-1 expression in medium follicles (R=-0.41).  Overall, correlation between E:P 
and gene expression was low for Experiment 1.  Data are expressed as correlation (R) values. 
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For Experiment 2, follicular fluid estradiol concentrations were lower, on average, than 
progesterone in small and medium follicles, but higher than progesterone in large follicles 
(Figure 2.17). 
 
Figure 2.17.  Estradiol and progesterone concentrations in follicular fluid from different-
sized sheep follicles—Experiment 2. 
Follicular fluid was pooled according to follicle diameter:  small (≤ 2.0 mm), medium (2.1-4.0 
mm) and large (4.1-6.0 mm).  After granulosa cells were separated by centrifugation, duplicate 
aliquots (200 µl total volume) of follicular fluid were analyzed by RIA without extraction.  
Progesterone concentrations were higher than estradiol in small and medium, but not large 
follicular fluid pools.  Data are expressed as mean ± SEM. 
Estradiol concentrations for small follicles averaged 0.29 ng/ml; Ewe 8018 (36h control; 
n=15 follicles) had the lowest (0.108 ng/ml) estradiol concentration while Ewe 8024 (24h 
control; n=12 follicles) had the highest (0.73 ng/ml) estradiol concentration of small follicle 
pools.  Estradiol concentrations for medium follicles averaged 2.73 ng/ml; Ewe 2 (36h PMSG; 
n=11 follicles) had the lowest (0.05 ng/ml) estradiol concentration, while Ewe 8076 (24h PMSG; 
n=8 follicles) had the highest (11.53 ng/ml) concentration of medium follicle pools.  Large 
follicles were present in two ewes: Ewe 184 (24h PMSG; n=2 follicles) and Ewe 8018 (36h 
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control; n=1 follicle).  Estradiol concentration for large follicles collected from Ewe 8018 was 
43.26 ng/ml and 120.93 ng/ml for Ewe 184.  Mean progesterone concentration in small follicles 
was 4.59 ng/ml and ranged from 1.37-8.14 ng/ml.  Progesterone concentration in medium 
follicles averaged 8.44 ng/ml and ranged from 4.36-15.63 ng/ml.  Large follicles had the highest 
mean progesterone concentration at 18.38 ng/ml, ranging from 13.27-23.49 ng/ml.  Overall, 
Experiment 2 had more pools with a higher proportion of healthy follicles (as determined by 
estradiol to progesterone ratio) than Experiment 1. 
Correlation between the estradiol to progesterone ratio was higher for Experiment 2 than 
Experiment 1 (Figure 2.18). 
 
Figure 2.18.  Correlation between estradiol to progesterone ratio and gene expression in 
small and medium sheep follicles—Experiment 2. 
Follicular fluid was pooled according to follicle diameter:  small (≤ 2.0 mm), medium (2.1-4.0 
mm).  After granulosa cells were separated by centrifugation, duplicate aliquots (200 µl total 
volume) of follicular fluid were analyzed by RIA without extraction.  Estradiol and progesterone 
concentrations were determined for each sample, and the ratio of estradiol to progesterone was 
calculated.  FSHR-2 had the highest correlation (R=0.98) to the E:P ratio in medium follicles.  
Correlation between E:P and LHR increased greatly in medium versus small follicles.  Overall, 
the correlation between E:P and gene expression was higher for Experiment 2 than Experiment 
1.  Data are expressed as correlation (R) values. 
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Correlation between E:P and gene expression in medium follicles was higher than in 
small follicles.  The LHR expression was correlated to E:P in medium follicles (R=0.75), but not 
in small follicles (R=0.08).  In small follicles, correlation between FSHR-3 and E:P was higher 
(R=0.65) than FSHR-1 (R=0.54)or FSHR-2 (R=0.42) .  In medium follicles, correlation between 
FSHR-2 and E:P was higher (R=0.98) than FSHR-1 (R=0.76) or FSHR-3 (R=0.64), even though 
FSHR-2 was the least expressed transcript. 
Serum progesterone concentrations were also determined using RIA.  For Experiment 1, 
serum progesterone values ranged from 0.35-0.67 ng/ml (Table 2.2). For Experiment 2, serum 
progesterone concentrations immediately prior to CIDR insertion ranged from 0.38-2.69 ng/ml.  
Serum progesterone concentrations just prior to euthanasia for the same ewes ranged from 0.40-
0.64 ng/ml. 
Estrous cycle length of ewes in Experiment 1 was similar (Table 2.2) except for one ewe:  
Ewe 4 exhibited shorter cycles that averaged 8.25 days.  Relative expression of FSHR variants 
within samples collected from Ewe 4 fell in the range of ewes with normal cycle length.  As 
such, those results were included.  The average number of follicles found per group for 
Experiment 1 and 2 are listed in Table 2.2. 
Follicle totals for Experiment 1 were as follows:  small (≤ 2.0 mm; n=109 total; n=8 
pools), medium (2.1 – 4.0 mm; n=54 total; n=8 pools) large (4.1-6.0 mm; n=1) and preovulatory 
(≥ 6.1 mm; n=7 total; n=3 pools).  No large follicles were analyzed for RNA expression in 
Experiment 1 due to sampling errors and/or lack of GC recovery during aspiration.  No 
significant differences were found between collection times (24, 36, or 48 hours after onset of 
estrus) for number of follicles within a size class. 
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Group 
 Time to 
Euthanasia 
Mean Cycle 
Length Number of Follicles Luteal Tissue (#) Serum Progesterone 
Exp 1 (hours) (days) ≤ 2 mm 2.1-4 mm 4.1-6 mm ≥ 6.1 mm CH CL CA (ng/ml)a (ng/ml)b 
24 22.83 ± 0.24 16.31 ± 0.48 11 ± 8.3 5.7 ± 0.7 0 2 ± 0  0 0.3 ± 0.3 2.0 ± 0.6 n/a 0.43 ± 0.06 
36 36.64 ± 0.83 16.80 ± 0.28 15.7 ± 5.0 8.3 ± 2.7 0.3 ± 0.3 0.3 ± 0.3 1.6 ± 0.3 1.0 ± 0.6 2.0 ± 0.6 n/a 0.54 ± 0.14 
48 49.33 ± 2.16 13.10 ± 4.85 14.5 ± 2.5 6.0 ± 3.0 0.5 ± 0.5 0 2.5 ± 0.5 1.5 ± 1.5 1.5 ± 0.5 n/a 0.55 ± 0.13 
Exp 2                       
24 CTRL 24.43 ± 0.05 n/a 17.5 ± 5.5 7.5 ± 0.5 0 0 1.0 ± 0 0.5 ± 0.5 0.5 ± 0.5 0.73 ± 0.31 0.46 ± 0.03 
24 PMSG 24.42 ± 0.09 n/a 19.5 ± 2.5 7.0 ± 1.0 1.0 ± 1.0 0 0 0.5 ± 0.5 0.5 ± 0.5 1.65 ± 1.05 0.57 ± 0.07 
36 CTRL 36.95 ± 0.02 n/a 18.0 ± 3.0 11.5 ± 5.5 0.5 ± 0.5 0 0.5 ± 0.5 0 0 0.45 ± 0 0.44 ± 0.04 
            36 PMSG 35.93 n/a 18 11 0 0 1 0 0 0.38 0.44 
 
 
Table 2.2.  Average values for sample collection parameters in Experiment 1 and 2.   
For Experiment 1, ewes were monitored through three estrous cycles then euthanized 24, 36, or 
48 hours after the onset of the next estrus.  For Experiment 2, ewes were euthanized 24 or 36 
hours after CIDR removal.  Data are presented as means ± SEM.  Ovarian structures were 
measured on the external surface of the ovary with a transparent ruler (to the nearest 0.5mm) and 
recorded.  All visible follicles were aspirated and follicular fluid from each pair of ovaries was 
pooled according to follicular diameter:  small (≤ 2.0 mm), medium (2.1-4.0 mm), large (4.1-6.0 
mm) and preovulatory (≥ 6.1 mm).  aBlood was collected prior to CIDR insertion (for 
Experiment 2).  bBlood was collected immediately prior to euthanasia (Experiment 1 and 2). 
Follicle totals for Experiment 2 were as follows:  small (≤ 2.0 mm; n=95 total; n=7 
pools), medium (2.1 – 4.0 mm; n=63 total; n=7 pools), large (4.1-6.0 mm; n=3 total; n=2 pools), 
and preovulatory (≥ 6.1 mm; n=0).  No significant differences were found between collection 
times (24 or 36 hours after CIDR removal) or treatment group (control vs. PMSG) when 
comparing numbers of follicles within a size class. 
Discussion 
In Experiment 1, we have shown that in untreated mature ewes allowed to cycle 
naturally, the relative expression of FSHR-3 was statistically greater than FSHR-1 in granulosa 
cells from medium (2.1-4.0 mm) follicles and tended to be higher in small follicles.  These 
results provide the first evidence that FSHR-3 is not a rare transcript in sheep, which is 
surprising in light of the large number of reports on the G protein-coupled form of the FSH 
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receptor (FSHR-1).  Based on its structure, the FSHR-3 variant has been described to function as 
a growth factor type-I receptor for FSH [52], thus FSHR-3 could stimulate proliferation of 
granulosa cells in growing follicles within the ovine ovary.  Regardless of follicle size, FSHR-3 
expression appeared to exceed that of FSHR-1, indicating that FSHR-3 may be much more 
important during follicular development than previously thought. 
In Experiment 2, FSHR variant expression profiles changed after progesterone treatment.  
Relative expression of FSHR variants was numerically higher in small (≤ 2.0 mm) than in 
medium follicles, which was opposite of that from Experiment 1.  This trend was present 
regardless of treatment or time (24 or 36 hours after CIDR removal) of tissue collection except 
for LHR expression, which was still higher in medium follicles.  Expression of LHR was 
expected to increase with increasing granulosa cell differentiation (and follicle diameter) [65-67] 
and this pattern was observed for both experiments. 
For both experiments, FSHR-1 appeared to be expressed in follicles of all sizes at 24, 36, 
and 48 hours after the onset of estrus or 24 and 36 hours after PMSG treatment.  These results 
agree with Tisdall et al (1995) who found FSHR to be expressed in follicles as small as the 
primary stage, with expression continuing thereafter, even in follicles beginning to undergo 
atresia [13].  However, Abdennebi et al. and many others have attempted to assess FSHR 
expression using primers or probes that would not discriminate between the different FSHR 
variants [65].  In the current study, care was taken to design primers such that specific variants of 
the FSHR would be discernable. 
Relative expression of FSHR-1 was the highest in large follicles following progesterone 
treatment, and lowest in preovulatory follicles in untreated ewes.  Relative expression of FSHR-2 
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was the lowest of FSHR variants, with expression only exceeding (although not significantly) 
that of FSHR-1 in preovulatory follicles. 
Other studies have been conducted that examined FSHR variant expression in both sheep 
and mice using RT-PCR and Western blotting.  In one study, immature mice (21d) were PMSG-
primed (5 IU) and ovaries were harvested 24 or 48 hours later [68].  A two-fold increase was 
seen in FSHR-3 expression over FSHR-1 in PMSG-primed mice; a corresponding increase in 
each receptor protein expression was also observed.  We did not see an increase in FSHR variant 
mRNA expression when ewes were hormone-primed with 500 IU PMSG; however, this dose of 
PMSG was chosen based on protocols (EAZI-BREED™ CIDR®, Pfizer New Zealand, Mt. 
Eden, Auckland) designed to stimulate out-of-season breeding.  McNatty et al. (1982) showed 
that PMSG (500 IU) priming can decrease atresia of small antral follicles during luteolysis in 
sheep [69].  McNatty et al. also saw that at 24 hours, the proportion of healthy and atretic 
follicles was restored to pretreatment levels.  Thus, because the effects of PMSG are relatively 
short-lived, sampling at 12 hours should be considered in the future.  In addition, dose-response 
experiments using PMSG in conjunction with measurement of FSHR variant expression would 
need to be performed before conclusions can be made as to whether PMSG stimulates FSHR 
variant expression in sheep. 
To help determine the health of follicles collected in these experiments, progesterone and 
estradiol concentrations for follicular pools were examined.  Steroid content of follicular fluid 
can be used as an indicator of follicular health status when looking at steroid profiles of 
individual follicles [70].  In the current study, follicles were pooled for each pair of ovaries based 
on size criteria, and accordingly, follicular health assessments based on estradiol and 
progesterone represented “average” follicle health and not actual health of each follicle in which 
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FSHR variants were measured.  Nevertheless, “average” follicle health may provide an initial 
indication of average FSHR variant expression based on stage of development.  Expression of 
FSHR variants in Experiment 2 were positively correlated with the estradiol to progesterone ratio 
in both small and medium follicles. 
Because follicles of similar sizes can have very different steroid profiles [38], assessing 
follicular health based on steroid content can be difficult.  Results for Experiment 1 were similar 
to those of Somchit et al.(2007), in that they observed higher progesterone than estradiol 
concentrations in pooled follicular fluid from follicles < 3.5 and ≥ 3.5 mm in diameter [71].  We 
saw the same trend in pools of fluid from small (≤ 2.0mm) or medium (2.1-4.0mm) follicles [29].  
Because progesterone concentrations were consistently higher than estradiol, we believe that a 
greater number of atretic small or medium follicles were collected than healthy (growing) small 
or medium follicles.  This is a reasonable assumption when considering the mechanism of 
follicular dynamics.  Once follicles reach the preovulatory size, estradiol is no longer the primary 
hormone produced by the follicle [70], so parameters in addition to the E:P ratio are necessary 
when assessing follicular health of that follicle size class. 
For Experiment 2, more pools of follicles were producing higher levels of estradiol.  This 
could be due to progesterone treatment, or because of PMSG treatment.  McNatty et al. (1982) 
found that after PMSG priming a greater proportion of large antral follicles were producing 
higher concentrations of estradiol than in control animals [69].  Our results echo this finding, 
because large (4.1-6.0 mm) follicles produced a higher amount of estradiol than smaller follicles. 
Serum progesterone was measured to help assess cycling status.  Circulating progesterone 
concentrations during the luteal phase of ewes are about 3 ng/ml, while progesterone 
concentrations during estrus are generally less than 1ng/ml [30, 72].  For Experiment 1, 
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progesterone concentrations collected just prior to euthanasia were under 1ng/ml, so any copora 
lutea observed when ovaries were examined after harvest were probably regressing.  Low serum 
progesterone concentrations, taken together with estrus behavior observations, provide 
compelling evidence that detection of onset of estrus was accurate.  For Experiment 2, serum 
progesterone concentrations in some ewes prior to CIDR insertion indicated the presence of 
functional corpora lutea.  However, serum progesterone concentrations just prior to euthanasia 
were under 1 ng/ml; the decline in serum progesterone concentrations shows that corpora lutea 
that were functioning before CIDR insertion (in some ewes) had regressed, and progesterone 
treatment/synchronization was sucessful. 
Overall number of follicles recovered from each ewe varied greatly.  Treatment with 
PMSG is thought to have little to no effect on the overall number of follicles > 1 mm in diameter 
[69].  Our results were consistent with previous findings in this regard. 
The diverse actions of FSH on follicles during the estrous cycle are well documented, and 
include stimulation of differentiation, hormone production, and proliferation of granulosa cells.  
Some of these actions are mediated by FSHR-1 through activation of adenylate cyclase and 
production of cAMP.  The G protein-coupled form of the receptor can also activate other 
signaling pathways, including extracellular regulated kinases (ERKs), and mitogen-activated 
protein kinases (MAPKs) [58].  The identification of the FSHR nucleotide sequence [5, 6] made 
it possible to detect alternatively spliced variants of the FSHR [7, 8].  The finding that FSHR-3 is 
the primary form of the FSHR in all follicle sizes examined in these experiments supports the 
idea that other forms of the FSHR, in addition to the well characterized G protein-coupled form, 
may participate in follicular growth and development during the sheep estrous cycle. 
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Appendix A - Protocols and Forms 
Aspiration Protocol 
• Consider both ovaries from a single ewe one sample. 
• Measure (using a transparent ruler, from the outer surface of the ovary) and chart ovarian 
structures (insert chart). 
• Aspirate follicular fluid from each follicle using a 1 cc syringe and a 20 gauge needle. 
• To ensure adequate granulosa cells are recovered, insert the needle into a follicle and aspirate 
the follicular fluid into the syringe and then gently push it back into the same follicle three 
times before removing the needle and moving to the next follicle.   
• Use a new syringe and needle for each ewe and each follicle size class. 
• Pool follicular fluid from follicles of similar diameter (small ≤ 2.0mm; medium 2.1 – 4.0 
mm; large 4.1-6.0mm; preovulatory ≥6.1 mm) into 1.5 µl microcentrifuge tubes. 
• Place tubes in microcentrifuge. 
• Centrifuge 2 minutes at 2300xg. 
• Aspirate supernatant and place in clean microcentrifuge tube – freeze in -20°C for E2/P4 
assay. 
• Cover each cell pellet with 0.5 ml PBS. 
• Resuspend by finger-flicking or gentle pipetting. 
• Centrifuge 1 minute at 2300xg. 
• Aspirate and discard PBS (leave a small amount to avoid disturbing the cell pellet). 
• Add 1 ml Trizol to each sample. 
• Resuspend the cell pellet by aspirating with a filtered 1 ml pipette tip. 
• Freeze in the -20°C (if less than one month) or -80°C (longer than one month) until RNA 
extraction. 
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RNA Extraction from Trizol samples 
• Trizol contains phenol, thus, it is the first step in a phenol/chloroform RNA extraction. 
• Thaw trizol samples (containing cell lysates in 1 ml Trizol) at room temp for 3-5 minutes. 
• Mix by inverting (about 10 times/minute) while thawing.  
• Go next door to the yellow flammables cabinet and take Chloroform:Isoamylalcohol (24:1) 
and  2-Propanol (Isopropanol) to the hood.  Measure approximately 1 ml of each into two 15 
ml conical tubes and leave (capped) in the hood.  Place large containers back into the 
flammables cabinet. 
• Take thawed Trizol samples, pipetman, tips, timer, and lab book to the hood. 
• Add 200 µl Chloroform:Isoamylalcohol to each Trizol sample (put excess ChCl3 into the 
Hazardous Waste container marked “Chloroform” in the hood). 
• Mix vigorously by hand for 15 seconds. 
• Incubate 3 minutes at room temperature (mix by hand several times while incubating). 
• Take capped samples to the microcentrifuge. 
• Place samples inside and ensure that the centrifuge fume cap is on. 
• Centrifuge for 15 minutes at full speed. 
• Label new tubes while this is spinning. 
• Take samples and new tubes back to the hood. 
• Aspirate aqueous fraction (clear liquid at the top, being careful to avoid the white protein 
layer).  
• Transfer to new tube – try to get about 500 µl of aqueous fraction removed/transferred. 
• Cap the old tubes and discard the remaining pink phase into the Haz. Waste bag in the hood 
(if you will be extracting protein or DNA from the samples, keep the pink phase; store it at   
– 80°C until extraction). 
• Add 500 µl Isopropanol to each sample (put excess into the Haz. Waste container marked “2-
propanol” in the hood). 
• Incubate 10 minutes at room temperature. 
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• Take capped samples to the microcentrifuge—always spin tubes such that the pellet forms on 
the hinge side of the microcentrifuge tube to avoid disturbing the pellet whenever it is 
invisible. 
• Centrifuge for 10 minutes at full speed—use fume cap. 
• Take samples back to the hood. 
• Remove the supernatant liquid and discard – into the “2-propanol” Haz. Waste bag in the 
hood (you may or may not be able to see an RNA pellet at this point; if no pellet is visible, 
leave a very thin layer of isopropanol in the bottom of the tube to avoid removing the RNA). 
• Add 1mL 75% EtOH (Ethanol and Water) to the precipitate and vortex very gently/briefly. 
• Centrifuge for 5 minutes at full speed (again, aligning all tubes the same way). 
• Preheat ~500 µl ddH20 at 65°C. 
• Aspirate EtOH carefully, keeping away from pellet. 
• Air dry pellets for 5-10 minutes. 
• Be sure all EtOH has evaporated; otherwise, RNA may not resuspend. 
• Add 15 µl preheated ddH20 and finger-flick to mix. 
• Incubate 10 minutes at 65°C.  
• Freeze extracted total RNA in the -80°C freezer (RNA is not very stable). 
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DNAse Treat RNA TURBO DNA-free Protocol 
• Use 0.5 mL microcentrifuge tubes 
• Prepare Master Mix on ice (prepare enough for ½ - 1 extra reaction): 
1 tube   *? tubes 
10X Turbo DNase Buffer  1.2 µl   ____µl 
TURBO DNase   0.5 µl   ____µl  
ddH2O    2.8 µl   ____µl 
4.5 µl    
• Add 4.5 µl master mix to each tube. 
• Add 7.5 µl RNA to each tube. 
• Incubate 40 minutes at 37°C (can use waterbath). 
• Vortex the DNase inactivation reagent. 
• Add 4 µl DNase inactivation reagent to each tube and finger flick to mix. 
• Incubate 3 minutes at room temp. 
• Finger flick several times to disperse the inactivation reagent. 
• Centrifuge for 1.5 minutes at 10,000 rpm. 
• Carefully transfer the supernatant containing the RNA into a new tube. 
• Avoid the inactivation reagent, as it can interfere with downstream reactions. 
• Final sample volume should be 10-12 µl. 
• Store in the -80°C freezer.  DNase treated RNA is unstable. 
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RT-PCR Protocol - SuperScript III First-Strand Synthesis SuperMix 
• Use this kit to convert DNase treated RNA to cDNA. 
• Starting material:  10 pg to 1 µg DNase treated (total) RNA 
• Combine the following kit components in a .2 ml or.5 ml thin-walled PCR tube on ice.  For 
multiple reactions, a master mix without RNA may be prepared: 
     1 rxn   *? rxns 
-2X RT Reaction Mix   10 µl   __ µ 
-RT Enzyme Mix   2  µl   __µl 
-RNA (10 pg to 1 µg total RNA) x  µl   __µl 
-ddH20    to 20 µl  __µl 
     20 µl       µl 
 
• Gently mix tube contents and incubate at 25°C for 10 minutes. 
• Incubate at 42°C for 50 minutes. 
• Terminate the reaction at 85°C for 5 minutes. 
• Chill on ice. 
• Add 1 µl of E. coli RNase H and incubate at 37°C for 20 minutes.  
• Use 1 µl of undiluted cDNA to prepare template for qPCR or store the reaction at -20°C until 
use. 
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Real-Time PCR Protocol - Platinum SYBR Green qPCR SuperMix-UDG with 
ROX 
• For multiple reactions, prepare a master mix of common components.   
• Prepare a 96-well plate map with template and primer set information.  For example, see 
table X. 
• Label 0.5 ml microcentrifuge tubes with primer set name, template name, or master mix.  
The following volumes have been scaled down to give a 20µl reaction volume; prepare the 
following on ice: 
Primer mastermixes: 
Component    Per reaction  x ? Rxns 
Platinum SYBR Green   10 µl   __ µl 
Forward Primer (250nM) .25 µl   __ µl 
Reverse Primer (250nM) .25 µl   __ µl 
ddH2O (to 15 µl)   4.5 µl   __ µl 
     15 µl per well  ? µl total 
• For each template, prepare a dilution. 
cDNA template:   Per well   x ? wells 
cDNA template   1 µl   __ µl 
ddH2O (to 5 µl)   4 µl   __ µl 
     5 µl per well  ? µl total 
• Once the primer master mixes and template are prepared, take them (on ice) to Colleen’s lab.   
• Load a 96-well plate according to the map you have prepared.   
• You will add 15 µl primer master mix and 5 µl diluted cDNA template per well for a final 
reaction volume of 20 µl. 
Program the ABI Prism 7500 as follows: 
50°C for 2 minutes hold (1 cycle) 
95°C for 2 minutes hold (1 cycle) 
40 cycles of: 
 95°C, 15 seconds 
 60°C, 30 seconds  
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DNA Gel Protocol 
• For a large, 2% agarose gel: 
• Use masking tape to seal the two open sides of the large gel cassette 
• Find the corresponding comb 
• Use 160 ml 1X TBE  
o 160 ml * 0.02 = 3.2 g agarose (in tall cabinet on east wall) 
• Combine 160 ml 1X TBE and 3.2 g agarose in a 500 ml Erlenmeyer flask, swirl 
• Microwave approximately 1 minute, 10 seconds. 
• Swirl 
• Microwave about 20 seconds longer, or until it begins to boil 
• Swirl 
• Cool by running cold tap water on the outside of the beaker, about 1 minute 
• Add 0.6 µl EtBr, swirl 
• Pour into taped gel cassette with comb in place 
• Remove air bubbles with a pipette tip 
• Let cool and gel set (about 10 min - while this is cooling, prepare samples) 
o place ~40 µl sample (DNA) and 4.5 µl Ficoll sample buffer in a microcentrifuge tube 
o repeat for each sample 
• Remove tape and comb 
• Put cooled gel (in cassette) into the large gel box 
• Fill with 1X TBE until gel is submerged 
• Load samples: 
o Use 6.5 µl (100bp) ladder in lane 1 
o Use 30 µl prepared sample per well 
• Run for ~2 hours at 70 volts (run toward red) 
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Estradiol RIA Protocol 
A. DIAGNOSTIC PRODUCTS CORPORATION (DPC) ESTRADIOL DOUBLE 
ANTIBODY KIT (# KE2D1) WITH MODIFICATIONS 
Dilute ovine follicular fluid from small and medium-sized follicles 1:100 in zero calibrator prior 
to assay.  Follicular fluid from large follicles may need dilution at 1:500. 
1. Estradiol Antiserum (# E2D1)  1 vial of lyophilized estradiol antiserum, raised in rabbits. 
Add 10 ml of Milli-Q-water.  Store refrigerated: stable at 4°C for 30 days after reconstitution.  
3. 125I Estradiol (#E2D2) 1 vial of iodinated synthetic Estradiol in liquid form, 11ml, 
3.5µCi.  Store refrigerated: stable at 4°C for 30 days after opening, or until the expiration date 
marked on the label. 
3. Estradiol Calibrators/Standards (# E2D3-9) One set of seven glass vials, labeled A 
through G, of Estradiol calibrators, with preservative.  The zero calibrator A (also referred to as 
RIA Buffer or Estradiol Calibrator Matrix) contains 6 ml, and the remaining calibrators B 
through G contain 3 ml each.  Store refrigerated: stable at 4°C for 30 days after opening. 
4. Precipitating Solution (# N6), 110 ml.  One vial consisting of goat anti-rabbit gamma 
globulin and dilute PEG in saline.  Store refrigerated: stable at 4°C for 30 days after opening. 
B. RIA STANDARDS and REAGENTS 
1. Assay Standards: Standards come ready for use in the kit. Note:  The concentration of 
unknown samples run in 100 µl volumes will be read off the standard curve at pg/ml values.  If 
sample dilutions are made, the concentration needs to be adjusted. 
Standard Vial labeled    Concentration at 100 µl per tube 
A.  0 pg/ml (Maximum Binding)    0 pg/ml 
B. 5 pg/ml      2.5 pg/ml 
C. 10 pg/ml      5 pg/ml 
D. 20 pg/ml      10 pg/ml 
E. 50 pg/ml      25 pg/ml 
F. 150 pg/ml      75 pg/ml 
G. 500 pg/ml      250 pg/ml 
2. Estradiol Antiserum  At least 10 minutes before use, reconstitute vial by adding 10 ml 
Milli-Q water or bring to room temperature (RT) if stored at 4°C.  Mix by gentle inversion. 
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3. Quality Controls  To ensure assay is running properly:  
QC1 Use standard C 100 µl = 5 pg/ml (four tubes – 2 for beginning and end of run) 
For Inter-assay controls (CV between assays): 
Make the following dilutions using an ovine follicular fluid (oFF) standard: 
QC2 1:100 dilution of oFF (495 µl RIA calibrator matrix + 5 µl oFF standard (four tubes)) 
For Intra-assay controls (CV within an assay): 
A second set of quality controls can be placed at the end of an assay greater than 200 tubes. 
A.  RIA PROTOCOL   
Note:  Rainin pipettes are used for standard and sample preparation.  Eppendorf repeater pipette 
is used for the addition of Estradiol Antiserum, 125I-Estradiol, and Precipitation Solution. 
1.  Set up: 
a. Label 12 x 75 mm polypropylene tubes:   
• Total Count  (TC, tubes 1 and 2). 
• Non-Specific Binding (NSB, tubes 3 and 4)  
• Maximum Binding (MB, tubes 5 and 6)  
• Standards (tubes 7-18; at least three additional standards can be added to the lower 
end of the curve, if desired). 
• Quality Controls (QC1, tubes 19 and 20; QC2, tubes 21 and 22; QC3, tubes 23 and 
24).   
• Samples will start at tube 25 and will be run in duplicate.   
b. Place tubes in racks on trays covered with lab bench paper.   
c. Bring all samples and RIA components, except Precipitating Solution, to RT before use. 
d. TC tubes are left empty at this point. 
e. To the NSB tubes, add 100 µl RIA calibrator matrix. 
f. To the MB tubes, add 100 µl RIA calibrator matrix. 
g. To the standard tubes (7-18), add 100 µl of each standard concentration (2.5 to 250 
pg/ml, B to G) in ascending order, in duplicate. 
h. To QC1, QC2, and QC3, add 100 µl of the indicated quality control. 
i. To tubes 25 and above, add samples.  Total volume is 100 µl.  Any dilutions are made in 
RIA calibrator matrix. 
2.  Assay 
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 a.  Add 30 µl of Estradiol Antiserum to all tubes except TC and NSB tubes (tubes 1-4). 
Vortex and incubate at RT for 2 hours. 
b. Add 75 µl of 125I-Estradiol to all tubes.  Cap TC tubes and set aside until counting. 
c. Vortex and incubate at RT for 1 hour. 
d. Write out amount (0.024 µCi/tube) of radioactivity, date, and initials on Rad tape and 
place on the covered tray containing the tubes. 
e. Add 1 ml of cold Precipitating Solution to all tubes except TC tubes.  
 Vortex and incubate at RT for 10 minutes. 
f. Centrifuge all tubes, except TC, at 3,100 x g for 15 min at 4°C.  
g. Take tubes (in centrifuge racks) to the radioactive hood.  Pour supernatant into metal pan.  
Keeping tubes inverted, rap sharply on paper towels, then move to dry paper towels.  
Every 5 minutes for ~ 15 minutes (3 times), rap the inverted tubes sharply on the paper 
towels and move to dry towels.  If no hanging droplets are present, proceed to counter. 
h. Count tubes for 1 min in Gamma Counter. 
i. Dispose liquid in bound 125I radioactive liquid waste carboy (0.02 µCi/tube) and paper in 
solid bound 125I radioactive waste can (0.004 µCi/tube).  
j. Use Assay Zap software and Estradiol.azm method to calculate Estradiol concentration in 
samples.   
D. ADDITIONAL MATERIALS FROM DPC 
 In addition to reagents supplied in the kit (# KE2D1), additional reagents may be needed 
depending on the number of samples to be assayed.  
1. Estradiol Antiserum (# E2D1) comes lyophilized; add 10 ml Milli-Q-water 
2. 125I Estradiol (#E2D2) contains 11 ml, 3.5 µCi 
3. Estradiol Calibrator Matrix (#10EDZ) contains 100 ml 
4. Precipitating Solution (#5N6), contains 260 ml or (#N6) contains 110 ml 
E.  REFERENCES 
1. Diagnostic Products Corporation.  Double Antibody Estradiol RIA protocol. 
2. Turzillo, A.M. and Fortune, J. E. 1990.  Suppression of the secondary FSH surge with bovine 
follicular fluid associated with delayed ovarian follicular development in heifers. J. Reprod. 
Fert. 89:643. 
3. Ireland, JLH, Ireland, JJ. 1994. Changes in expression of inhibin/activin , A and B subunit 
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messenger ribonucleic acids following increases in size and during different stages of 
differentiation or atresia of non-ovulatory follicles in cows. Biol Reprod 50:492-501. 
70 
 
Progesterone RIA Protocol 
Siemens Medical Solutions Diangostics Progesterone COAT-A-COUNT Assay (#TKPG1) 
All components must be at room temperature before use. 
Prepare ovine follicular fluid samples prior to assay by diluting 1 µl follicular fluid in 49 µl zero 
calibrator. 
All components must be at room temperature before use. 
1. Plain tubes: Label four uncoated 12x75mm polypropylene tubes TC (total counts) and NSB 
(nonspecific binding) in duplicate. 
Coated tubes: Label fourteen Progesterone Ab-coated tubes with standard curve 
concentrations, starting with 0 ng/ml in duplicate.  At least two additional standards can be 
added to the lower end of the curve, if desired.  Label additional Ab-coated tubes, also in 
duplicate for controls and samples. 
2. Pipette 100 µl of the zero calibrator into the NSB and 0 ng/ml tubes, and 100 µl of each of 
the standard curve calibrators into its designated tubes.  Pipette 100 µl of each control and 
unknown samples into the tubes prepared. 
Because progesterone has a tendency to adsorb to plastic, and even more so to glass, it is 
important to dispense each sample into the very bottom of each tube.  In addition, it is also 
important to coat the pipette tip by rinsing a few times in the sample before making the 
transfer to the tube.  Also, change tips between each standard and sample. 
Samples expected to exceed 40 ng/ml should be diluted in the zero calibrator before assay. 
3. Add 1.0 ml of 125 I Progesterone to every tube.  Vortex. 
No more than ten minutes should elapse during dispensing of the tracer.  Set the TC tubes 
aside for counting; they require no further processing. 
4. Incubate for 3 hours at room temperature. 
5. Decant thoroughly. 
Removing all visible moisture will greatly enhance precision.  Using a foam decanting rack, 
decant the contents of all tubes (except for TC) in the radioactive hood (in an appropriate 
container) and allow them to drain on paper towels for 2 or 3 minutes.  The strike tubes 
sharply on paper towels to remove residual droplets. 
6. Count for 1 minute with gamma counter. 
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RNA Quality Protocol-Agilent 2100 Bioanalyzer with Agilent 6000 Nano Kit 
The Bioanalyzer is located in the COBRE lab in Coles Hall.  You must register for an 
account with Kalidou Ndiaye to use this machine. 
Turn on waterbath (heat to 70 C) 
Preparing the Gel-Dye Mix 
1. Allow the RNA 6000 Nano dye concentrate (blue) to equilibrate to room temperature for 30 
minutes. 
2. Spin down the dye, filtered gel, and marker for about 30 seconds. 
3. Add 65 µL filtered gel (red) to 1 µl dye and vortex for about 15 seconds. 
4. Centrifuge at 13000xg for 10 minutes at room temperature.  Use within one day. 
While this is spinning, go upstairs to room 223 and get an aliquot of Nano ladder from the 
freezer.  Place on ice. 
Denature 1.5 µl RNA aliquots at 70 C for 2 minutes, then place on ice. 
Loading the Gel-Dye Mix 
1. Put a new RNA 6000 Nano chip on the chip priming station 
2. Pipette 9.0 µl of gel-dye mix into the well marked G – with circle around it. 
3. Make sure the plunger is positioned at 1 ml and then close the chip priming station (you will 
have to push down hard – till you hear a click). 
4. Press the plunger until it is held by the clip. 
5. Wait for exactly 30 seconds, then release the clip. 
6. Wait for 5 seconds.  Slowly pull back plunger to 1 ml position. 
7. Open chip priming station and pipette 9.0 ml of gel-dye mix into the wells marked G (no 
circle). 
8. Discard the remaining gel-dye mix. 
Loading the Agilent RNA 6000 Nano Marker 
1. Pipette 5 µl of RNA 6000 Nano marker (green) in all 12 sample wells and in the well marked 
ladder. 
Loading the Ladder and Samples 
1. Pipette 1 µl of prepared ladder in well marked ladder. 
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2. Pipette 1 µl of sample into each of the 12 sample wells.  Pipette 1 µl of RNA 6000 Nano 
marker (green) into each unused sample well (final reaction volume of each sample well 
should be 6 µl). 
3. Put the chip horizontally in the adapter of the IKA vortexer and vortex for 1 minute at 2400 
rpm. 
4. Run the chip in the Agilent 2100 Bioanalyzer within 5 minutes. 
5. Select  - Assay, Electrophoresis, RNA, Eukaryotic RNA Nano 
6. Select Start 
7. Run will take about 25 minutes to complete. 
8. After run, click ok, then “Data and Assay” 
9. Double click in the sample name field to rename samples, then click the save icon. 
10. View results – open a new Word document.  Print screen in the 2100 software and paste into 
the word document.  When finished, save the Word document to the desktop (it will remain 
on the desktop for a few days).  Files are permanently stored in the 2100 software, according 
to date.
73 
 
Appendix B - Reagents and Supplies 
  
     Catalog  
RNA Isolation Company      Number 
TRIzol Reagent  Invitrogen 15596-026 
Chloroform Fisher Scientific C606-4 
Isoamyl Alcohol Sigma I-3643 
2-propanol (Isopropanol) Fisher Scientific A464-4 
Ethanol     
Nuclease-Free Water Ambion AM9937 
 DNAse Treatment     
TURBO DNA-free Ambion AM1907 
Reverse Transcription     
SuperScript III Invitrogen 11752-050 
Quantitative PCR (Real-Time) 
  Platinum SYBR Green with ROX Invitrogen 1173-038 
Protein Isolation 
  M-PER Mammalian Extraction Reagent Pierce PI78503 
SDS-PAGE     
Ready Gels 12% TRIS-HCL (50 μL/well) BIO-RAD 161-1156 
Precision Plus Standard Dual Color Ladder BIO-RAD 161-0374 
10X Tris/Glycine/SDS Buffer BIO-RAD 161-0732 
Laemmli Sample Buffer BIO-RAD 161-0737 
2-Mercaptoethanol (β-Mercaptoethanol) Sigma M-3148 
DPBS w/o calcium chloride, w/o magnesium chloride Gibco 14190-144 
Coomassie Brilliant Blue R-250 BIO-RAD 161-0400 
Western Blotting 
  10X TBS BIO-RAD 170-6435 
Methanol Fisher Scientific A452-4 
NP-40 Alternative CALBIOCHEM 492016 
Tween-20 BIO-RAD 
 Carnation Instant Nonfat Dry Milk     
Super Signal West Femto Maximum Sensitivity Substrate Pierce 34095 
Ready Gel Blotting Sandwiches, Immun-Blot PVDF 7x8.5cm BIO-RAD 162-0218 
R3 Primary Antibody (chicken anti-FSH-R3) 
  Secondary Antibody (goat-anti chicken IgY-HRP) Santa-Cruz sc-2901 
R1 Primary Antibody (chicken anti-FSH-R1)     
R2 Primary Antibody (chicken anti-FSH-R2) 
  10x Tris/Glycine Buffer  BIO-RAD 161-0734 
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Company 
 
Catalog 
Number 
DNA Isolation     
Dneasy Tissue Kit Qiagen 69504 
DNA gel 
  Agarose I MIDSCI 0710-100G 
Ethidium Bromide Fisher Biotech BP102-5 
Cell Culture 
  Dulbecco's Phosphate Buffered Saline 1X w/CaCl, w/MgCl Gibco 14040-133 
McCoy 5A Medium Gibco 16600-082 
Fetal Bovine Serum Gibco 16600-044 
Penicillin/Streptomycin Stock (5000units/5000 µg/mL) Gibco 15070-063 
Geneticin (G418) (50 mg/mL) Gibco 10131-035 
Trypsin 
  EDTA     
DMSO 
  Falcon T25 Flasks .2μm vented blue plug seal cap Becton Dickinson 353109 
Costar 6 well cell culture cluster plates 5/bag, 100/case sterile Corning, Inc. 3506 
Pasteur Pipettes Fisher Scientific 13-678-20C 
Other: 
  Aloetouch Gloves (small) Fisher Healthcare 23-667-200A 
Diamond Grip Latex Gloves (medium, A&P) Fisher Healthcare 11-462-67C 
Diamond Grip Latex Gloves (large, A&P) Fisher Healthcare 11-462-67D 
Aurelia Protégé Nitrile gloves (medium, A&P) MIDSCI 93997 
Aurelia Protégé Nitrile gloves (large, A&P) MIDSCI 93998 
MAXY clear .6mL Microcentrifuge Tubes MIDSCI T-060-C 
Fiber Pads Package of 4 (for transfer) BIO-RAD 170-3933 
Rnase-free Tips all sizes (AM12635-AM12665) Ambion 
 Lab Bench Paper 20x250 roll Fisher Scientific 14-206-65 
 
 
 
 
 
